



Capacities/Research Potential  
FP7-REGPOT-2012-2013-1

Project No. 316254  
**BASTION**

*“From Basic to Translational Research in Oncology”*

Deliverable D6.3

**Report**

**Final plan for the use and dissemination of foreground**

Project start date:	1.09.2012
Project duration:	42 M
Due date of deliverable:	31.08.2015
Actual submission date:	31.08.2015
Dissemination level:	PUBLIC



## Table of content

	page
1. Introduction.....	3
2. Dissemination of the foreground.....	4
2.1. Peer-reviewed journal articles.....	4
2.2. Posters and presentations.....	20
3. Planned use and dissemination.....	29
4. Conclusions.....	38

All reports are available on BASTION Webpage: <http://bastion.wum.edu.pl/en/raporty/>



## **Executive summary**

This document describes in a detailed manner the terms of use and dissemination of knowledge arising from the BASTION project. The following dissemination activities are described: research publications, conference meetings, web-site, patenting and educational activities. In total 177 research publications have been published so far in peer-reviewed scientific journals. A complete list of peer reviewed articles, oral presentation, poster presentations and other is given. Moreover, the final plan for the use and dissemination of foreground provides a picture of dissemination and research activities to be undertaken in the Project.

## **1. Introduction**

### **1.1. Scope of this document**

This report aims to describe in detail the actions taken under the BASTION project and description of planned activities after its completion.

### **1.2 The aim of the BASTION project**

The major aim of the BASTION project was to overcome existing shortcomings of MUW by strengthening research potential in basic and translational oncology. To achieve this goal a number project operating objectives were envisioned:

- I. Increase scientific dialogue between MUW, top academic research centers and innovation driven SMEs via secondments of scientific and innovation management staff.
- II. Facilitate the exchange of scientific ideas, share research results and engage in new collaborations, as well as to increase the impact of translational studies in oncology by knowledge sharing and implementing targeted dissemination actions involving all relevant stakeholders at the regional, national and European levels by organizing an international conference on “translational research in oncology in new member state economies” and five thematic workshops; supporting attendance at international conferences and training workshops, promoting BASTION activities at relevant international conferences and other events organized or co-organized by international partners, engaging key stakeholders and decision makers in BASTION from the very beginning of the project, educating the public on the benefits of translational research for public health, influencing public health policy on cancer prevention in order to close the gap between EU-15 and convergence regions of CEE
- III. Build human potential by recruiting 12 researchers with international experience in basic and clinical oncology (one new research group leader and 11 post-docs) with particular emphasis on scientists and professionals returning from abroad, as well as



- two IT professionals with background in bioinformatics to accelerate the establishment of an independent research group
- IV. Build the capacity of MUW's research base in molecular oncology and translational studies by purchasing state-of-the art equipment items
  - V. Facilitate and increase the impact of translational studies in oncology by hiring a professional innovation manager, implementing efficient IP protection and innovation management schemes, organizing joint events with SME partners as well as the research / academic partners to transfer best-practice in science – industry cooperation and promote innovation driven translational research
  - VI. Improve, update and professionalize project management processes at MUW by hiring an experienced project manager
  - VII. Evaluate the transition and increased potential of MUW to engage in basic and translational research in oncology by a team of external experts recruited by the European Commission and working closely with the Project International Advisory Board and the Management Committee

## 2. Dissemination of the foreground

A detailed report on dissemination is provided in deliverables D2.6 and D2.7. Altogether, numerous actions have been undertaken, including off-line (such as workshops, conferences, interviews, meetings) and on-line (including webpages, social media as well as videos) activities. In the course of the project its team leaders and newly employed researchers delivered numerous interviews on reputable and nationwide radio and TV channels such as TVN, Polskie Radio Jedynka, TOK FM Radio. Also in brand and national press numerous articles appeared disseminating the foreground. Events such as Pharma Days (described in deliverable D5.5) were a unique opportunity to disseminate information on the research activities of BASTION participants to international researchers with an outstanding scientific expertise in experimental and clinical oncology and to biopharmaceutical companies from all over the world.

### 2.1. Peer-reviewed journal articles

BASTION team leaders and newly hired researchers published 182 research articles between Sept 1<sup>st</sup> 2012 and August 31<sup>st</sup> 2015. The list of articles (itemized in the table below) shows the scientific potential of BASTION researchers.

No	Publication
1.	Iwanicka-Pronicka K, Pollak A, Skórka A, Lechowicz U, Pajdowska M, Furmanek M, Rzeski M, Korniszewski L, Skarzyński H, Płoski R. Postlingual hearing loss as a mitochondrial 3243A>G mutation phenotype. PLoS One. 2012;7(10):e44054.
2.	Nowak I, Magott-Procelewska M, Kowal A, Miazga M, Wagner M, Niepiekło-Miniewska W, Kamińska M, Wiśniewski A, Majorczyk E, Klinger M, Łuszczek W, Pawlik A, Płoski R, Barcz E, Senitzer D, Kuśnierczyk P. Killer immunoglobulin-like receptor (KIR) and HLA genotypes affect the outcome of allogeneic kidney



	transplantation. PLoS One. 2012;7(9):e44718.
3.	Chojnicka I, Sobczyk-Kopciol A, Fudalej M, Fudalej S, Wojnar M, Waszkiewicz A, Broda G, Strawa K, Pawlak A, Krajewski P, Ploski R. No association between MTHFR C677T polymorphism and completed suicide. <i>Gene</i> . 2012 Dec 10;511(1):118-21
4.	Moraitou M, Dimitriou E, Mavridou I, Michelakakis H, Georgouli H, Ploski R, Pollak A. Transferrin isoelectric focusing and plasma lysosomal enzyme activities in the diagnosis and follow-up of hereditary fructose intolerance. <i>Clin Chim Acta</i> . 2012 Oct 9;413(19-20):1714-5.
5.	Chojnicka I, Ploski R. Polish version of the ADI-R (Autism Diagnostic Interview-Revised). <i>Psychiatria Polska</i> . 2012 Sep-Oct;46(5):781-9.
6.	Kusio-Kobialka M, Podszywalow-Bartnicka P, Peidis P, Glodkowska-Mrowka E, Wolanin K, Leszak G, Seferynska I, Stoklosa T, Koromilas AE, Piwocka K. The PERK-eIF2 $\alpha$ phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells. <i>Cell Cycle</i> . 2012 Nov 1;11(21):4069-78
7.	Winiarska M, Nowis D, Bil J, Glodkowska-Mrowka E, Muchowicz A, Wanczyk M, Bojarczuk K, Dwojak M, Firczuk M, Wilczek E, Wachowska M, Roszczenko K, Miaczynska M, Chlebowska J, Basak GW, Golab J. Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity. <i>J Biol Chem</i> . 2012 Sep 14;287(38):31983-93
8.	Kornasiewicz O, Bojarczuk K, Bugajski M, Golab J, Krawczyk M. Application of a proteomic approach to identify proteins associated with primary graft non-function after liver transplantation. <i>Int J Mol Med</i> . 2012 Oct;30(4):755-64.
9.	Włodarski KH, Włodarski P, Galus R, Mazur S. Adipose mesenchymal stem cells. Their characteristics and potential application in tissue repair. <i>Pol Orthop Traumatol</i> . 2012 Dec 15;77:97-9.
10.	Włodarski KH, Galus R, Brodzikowska A, Włodarski PK. The adipocyte component of bone marrow in heterotopic bone induced by demineralized incisor grafts. <i>Folia Histochem Cytobiol</i> . 2012 Oct 8;50(3):444-9.
11.	Zucchelli M, Ström S, Holm F, Malmgren H, Sahlén S, Religa P, Hovatta O, Kere J, Inzunza J. In vivo differentiated human embryonic stem cells can acquire chromosomal aberrations more frequently than in vitro during the same period. <i>Stem Cells Dev</i> . 2012 Dec 10;21(18):3363-71.
12.	Religa P. The future application of induced pluripotent stem cells in vascular regenerative medicine. <i>Cardiovasc Res</i> . 2012 Dec 1;96(3):348-9.
13.	Swierniak M, Wojcicka A, Czetwertynska M, Stachlewska E, Maciag M, Wiechno W, Gornicka B, Bogdanska M, Koperski L, de la Chapelle A, Jazdzewski K. In-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma. <i>J Clin Endocrinol Metab</i> . 2013 Aug;98(8):E1401-9.
14.	He H, Li W, Wu D, Nagy R, Liyanarachchi S, Akagi K, Jendrzewski J, Jiao H, Hoag K, Wen B, Srinivas M, Waidyaratne G, Wang R, Wojcicka A, Lattimer IR, Stachlewska E, Czetwertynska M, Dlugosinska J, Gierlikowski W, Ploski R, Krawczyk M, Jazdzewski K, Kere J, Symer DE, Jin V, Wang Q, de la Chapelle A. Ultra-rare mutation in long-range enhancer predisposes to thyroid carcinoma with high penetrance. <i>PLoS One</i> . 2013 May 14;8(5):e61920.
15.	Liyanarachchi S, Wojcicka A, Li W, Czetwertynska M, Stachlewska E, Nagy R,



	Hoag K, Wen B, Ploski R, Ringel MD, Kozłowicz-Gudzinska I, Gierlikowski W, Jazdzewski K, He H, de la Chapelle A. Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma. <i>Thyroid</i> . 2013 Dec;23(12):1532-40
16.	He H, Bronisz A, Liyanarachchi S, Nagy R, Li W, Huang Y, Akagi K, Saji M, Kula D, Wojcicka A, Sebastian N, Wen B, Puch Z, Kalemba M, Stachlewska E, Czetwertynska M, Dlugosinska J, Dymecka K, Ploski R, Krawczyk M, Morrison PJ, Ringel MD, Kloos RT, Jazdzewski K, Symer DE, Vieland VJ, Ostrowski M, Jarzab B, de la Chapelle A. SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility. <i>J Clin Endocrinol Metab</i> . 2013 May;98(5):E973-80
17.	Wojcicka A, Bassett JH; Williams GR 2013 Mechanisms of action of thyroid hormones in the skeleton. <i>Biochim Biophys Acta Jul</i> ;1830(7):3979-86
18.	Piekuelko-Witkowska A, Kedzierska H, Poplawski P, Wojcicka A, Rybicka B, Maksymowicz M, Grajkowska W, Matyja E, Mandat T, Bonicki W, Nauman P. Alternative splicing of iodothyronine deiodinases in pituitary adenomas. Regulation by oncoprotein SF2/ASF <i>Biochim Biophys Acta</i> 2013;1832(6):763-72
19.	Saracyn M, Płoski R, Niemczyk S. Contemporary role of medical genetics in internal medicine. <i>Arch Med Sci</i> . 2013 Aug 30;9(4):594-600.
20.	Kostrzewa G, Broda G, Konarzewska M, Krajewki P, Płoski R. Genetic polymorphism of human Y chromosome and risk factors for cardiovascular diseases: a study in WOBASZ cohort. <i>PLoS One</i> . 2013 Jul 25;8(7):e68155
21.	Jóźwiak J, Sontowska I, Płoski R. Frequency of TSC1 and TSC2 mutations in American, British, Polish and Taiwanese populations. <i>Mol Med Rep</i> . 2013 Sep;8(3):909-13.
22.	Niepiekło-Miniewska W, Majorczyk E, Matusiak L, Gendzekhadze K, Nowak I, Narbutt J, Lesiak A, Kuna P, Ponińska J, Pietkiewicz-Sworowska A, Samoliński B, Płoski R, Szepietowski JC, Senitzer D, Kuśnierczyk P. Protective effect of the KIR2DS1 gene in atopic dermatitis. <i>Gene</i> . 2013 Sep 25;527(2):594-600.
23.	Ołdak M, Przybylska D, Kosińska J, Federowicz A, Woźniak K, Płoski R, Kowalewski C. Novel de novo mutation in KRT14 underlies a localized form of epidermolysis bullosa simplex. <i>Eur J Dermatol</i> . 2013 May-Jun;23(3):404-6.
24.	Pazik J, Ołdak M, Lewandowski Z, Podgórska M, Sitarek E, Płoski R, Gałazka Z, Kwiatkowski A, Malejczyk J, Durlik M. Uridine diphosphate glucuronosyltransferase 2B7 variant p.His268Tyr as a predictor of kidney allograft early acute rejection. <i>Transplant Proc</i> . 2013 May;45(4):1516-9.
25.	Caraballo Cortés K, Zagordi O, Laskus T, Płoski R, Bukowska-Ośko I, Pawełczyk A, Berak H, Radkowski M. Ultradeep pyrosequencing of hepatitis C virus hypervariable region 1 in quasispecies analysis. <i>Biomed Res Int</i> . 2013;2013:626083.
26.	Tesson F, Saj M, Uvaize MM, Nicolas H, Płoski R, Bilińska Z. Lamin A/C mutations in dilated cardiomyopathy. <i>Cardiology Journal</i> . 2014;21(4):331-42.
27.	Saj M, Bilinska ZT, Tarnowska A, Sioma A, Bolongo P, Sobieszczanska-Malek M, Michalak E, Golen D, Mazurkiewicz L, Malek L, Walczak E, Fidzińska A, Grzybowski J, Przybylski A, Zielinski T, Korewicki J, Tesson F, Ploski R. LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies. <i>BMC Med Genet</i> . 2013 May 23;14:55
28.	Jurecka-Lubieniecka B, Ploski R, Kula D, Krol A, Bednarczyk T, Kolosza Z, Tukiendorf A, Szpak-Ulczo S, Stanjek-Cichoracka A, Polanska J, Jarzab B. Association between age at diagnosis of Graves' disease and variants in genes



	involved in immune response. PLoS One. 2013;8(3):e59349.
29.	Chojnicka I, Gajos K, Strawa K, Broda G, Fudalej S, Fudalej M, Stawiński P, Pawlak A, Krajewski P, Wojnar M, Płoski R. Possible association between suicide committed under influence of ethanol and a variant in the AUTS2 gene. PLoS One. 2013;8(2):e57199.
30.	Nehring P, Mrozikiewicz-Rakowska B, Sobczyk-Kopciół A, Makowski A, Krasnodębski P, Płoski R, Broda G, Karnafel W. Osteoprotegerin gene rs2073617 and rs3134069 polymorphisms in type 2 diabetes patients and sex-specific rs2073618 polymorphism as a risk factor for diabetic foot. Pol Arch Med Wewn. 2013;123(4):176-82.
31.	Szczepańska M, Mostowska A, Wirstlein P, Malejczyk J, Płoski R, Skrzypczak J, Jagodziński PP. Polymorphic variants of DNMT3A and the risk of endometriosis. Eur J Obstet Gynecol Reprod Biol. 2013 Jan;166(1):81-5
32.	He H, Li W, Wu D, Nagy R, Liyanarachchi S, Akagi K, Jendrzewski J, Jiao H, Hoag K, Wen B, Srinivas M, Waidyaratne G, Wang R, Wójcicka A, Lattimer IR, Stachlewska E, Czetwertynska M, Dlugosinska J, Gierlikowski W, Płoski R, Krawczyk M, Jazdzewski K, Kere J, Symer DE, Jin V, Wang Q, de la Chapelle A. Ultra-rare mutation in long-range enhancer predisposes to thyroid carcinoma with high penetrance. PLoS One. 2013 May 14;8(5):e61920.
33.	Gaciong Z, Siński M, Lewandowski J. Blood pressure control and primary prevention of stroke: summary of the recent clinical trial data and meta-analyses. Curr Hypertens Rep. 2013 Dec;15(6):559-74.
34.	Lewandowski J, Sinski M, Symonides B, Korecki J, Rogowski K, Judycki J, Sieczych A, Możeńska O, Gaciong Z. Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study. Urology. 2013 Sep;82(3):660-5.
35.	Zdrojewski T, Rutkowski M, Bandosz P, Gaciong Z, Jędrzejczyk T, Solnica B, Pencina M, Drygas W, Wojtyniak B, Grodzicki T, Piwoński J, Wyrzykowski B. Prevalence and control of cardiovascular risk factors in Poland. Assumptions and objectives of the NATPOL 2011 Survey. Kardiologia Pol. 2013;71(4):381-92.
36.	Antikainen RL, et al. incl. Gaciong Z among >250 co-authors. Prevalence and covariates of electrocardiographic left ventricular hypertrophy in the Hypertension in the Very Elderly Trial. J Hypertens. 2013 Jun;31(6):1224-32
37.	Schulman S, et al. incl. Gaciong Z among >450 co-authors. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):709-18.
38.	Agnelli G, et al. incl. Gaciong Z among >400 co-authors. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699-708
39.	Nieborowska-Skorska M, Hoser G, Hochhaus A, Stoklosa T, Skorski T. Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice. Leukemia. 2013 Nov;27(11):2253-4.
40.	Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T, Nieborowska-Skorska M, Maier J, Kerstiens L, Koptyra M, Müller MC, Modi H, Stoklosa T, Seferynska I, Bhatia R, Holyoake TL, Koschmieder S, Skorski T. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood. 2013 May 16;121(20):4175-83.
41.	Machnicki MM, Glodkowska-Mrowka E, Lewandowski T, Ploski R, Wlodarski P,



	Stoklosa T. ARMS-PCR for detection of BRAF V600E hotspot mutation in comparison with Real-Time PCR-based techniques. <i>Acta Biochim Pol.</i> 2013;60(1):57-64
42.	Stoklosa T, Glodkowska-Mrowka E, Hoser G, Kielak M, Seferynska I, Włodarski P. Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia. <i>Exp Hematol.</i> 2013 May;41(5):462-9.
43.	Slupianek A, Falinski R, Znojek P, Stoklosa T, Flis S, Doneddu V, Pytel D, Synowiec E, Blasiak J, Bellacosa A, Skorski T. BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability. <i>Leukemia.</i> 2013 Mar;27(3):629-34.
44.	Firczuk M, Gabrysiak M, Barankiewicz J, Domagala A, Nowis D, Kujawa M, Jankowska-Steifer E, Wachowska M, Glodkowska-Mrowka E, Korsak B, Winiarska M, Golab J. GRP78-targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy. <i>Cell Death Dis.</i> 2013 Jul 25;4:e741.
45.	Rak B, Szlufik S, Grajkowska W, Perek D, Dembowska-Bagińska B, Filipek I, Daszkiewicz P, Włodarski P, Józwiak J. Upregulation of mitogen-activated protein kinase in ganglioglioma. <i>Folia Neuropathol.</i> 2013;51(4):283-9.
46.	Włodarski KH, Galus R, Brodzikowska A, Włodarski PK. Sclerostin, an osteocytes-derived bone-forming inhibitor. <i>Pol Orthop Traumatol.</i> 2013 Jul 1;78:151-4.
47.	Włodarski P, Galus R, Brodzikowska A, Włodarski KH. Osteogenic efficiency of demineralized and lyophilized xenogeneic bone and syngeneic dentine implants in mice. <i>Folia Biol (Krakow).</i> 2013;61(1-2):25-9.
48.	Włodarski KH, Szczesny G, Kuzaka B, Włodarski PK. Long-term preservation of Bone Morphogenetic Activity in stored demineralized murine incisors. <i>Pol Orthop Traumatol.</i> 2013 Apr 4;78:97-100.
49.	Sajjad EA, Zieliński G, Maksymowicz M, Hutnik Ł, Bednarczuk T, Włodarski P. mTOR is frequently active in GH-secreting pituitary adenomas without influencing their morphopathological features. <i>Endocr Pathol.</i> 2013 Mar;24(1):11-9.
50.	Majewski S, Rudnicka I. Sexually transmitted diseases in Poland in 2011. <i>Przegl Epidemiol.</i> 2013;67(2):283-6, 379-81.
51.	Młynarczyk-Bonikowska B, Majewska A, Malejczyk M, Młynarczyk G, Majewski S. Antiviral medication in sexually transmitted diseases. Part I: HSV, HPV. <i>Mini Rev Med Chem.</i> 2013 Nov;13(13):1837-45
52.	Majewski S, Rudnicka I. [Sexually transmitted diseases in Poland in 2010]. <i>Przegl Epidemiol.</i> 2012;66(3):453-8.
53.	Crequer A, Picard C, Pedergnana V, Lim A, Zhang S-, Abel L, Majewski S, Casanova J, Jablonska S, Orth G, Jouanguy E. EVER2 deficiency is associated with mild T-cell abnormalities. <i>J Clin Immunol</i> 2013; 33: 14-21
54.	MiR Johansson J, Berg T, Kurzejamska E, Pang MF, Tabor V, Jansson M, Roswall P, Pietras K, Sund M, Religa P, Fuxe J. -155-mediated loss of C/EBP $\beta$ shifts the TGF- $\beta$ response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. <i>Oncogene.</i> 2013 Dec 12;32(50):5614-24.
55.	Religa P, Cao R, Religa D, Xue Y, Bogdanovic N, Westaway D, Marti HH, Winblad B, Cao Y. VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival. <i>Sci Rep.</i> 2013;3:2053.
56.	Grudzinska MK, Kurzejamska E, Bojakowski K, Soin J, Lehmann MH, Reinecke H, Murry CE, Soderberg-Naucler C, Religa P. Monocyte chemoattractant protein 1-mediated migration of mesenchymal stem cells is a source of intimal hyperplasia.





	Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1271-9
57.	Taher C, de Boniface J, Mohammad AA, Religa P, Hartman J, Yaiw KC, Frisell J, Rahbar A, Söderberg-Naucler C. High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. <i>PLoS One</i> . 2013;8(2):e56795.
58.	Czystowska M, Gooding W, Szczepanski MJ, Lopez-Abaiteo A, Ferris RL, Johnson JT, Whiteside TL. The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC. <i>Clin Cancer Res</i> . 2013 Feb 15;19(4):889-99.
59.	Pyrzynska B, Banach-Orlowska M, Teperek-Tkacz M, Miekus K, Drabik G, Majka M, Miaczynska M. Multifunctional protein APPL2 contributes to survival of human glioma cells. <i>Mol Oncol</i> . 2013 Feb;7(1):67-84.
60.	Bielinska B, Gaj P, Kluska A, Nowakowska D, Balabas A, Dabrowska M, Niwinska A, Gruchota J, Zub R, Skasko E, Steffen J, Ostrowski J, Siedlecki JA. Association of the BRCA1 promoter polymorphism rs11655505 with the risk of familial breast and/or ovarian cancer. <i>Fam Cancer</i> . 2013 Dec;12(4):691-8
61.	Wiera G, Wozniak G, Bajor M, Kaczmarek L, Mozrzymas JW. Maintenance of long-term potentiation in hippocampal mossy fiber-CA3 pathway requires fine-tuned MMP-9 proteolytic activity. <i>Hippocampus</i> . 2013 Jun;23(6):529-43.
62.	Wojcicka A, Swierniak M, Kornasiewicz O, Gierlikowski W, Maciag M, Kolanowska M, Kotlarek M, Gornicka B, Koperski L, Niewinski G, Krawczyk M, Jazdzewski K. Next generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma. <i>Int J Biochem Cell Biol</i> . 2014 Aug;53:208-17.
63.	Wójcicka A, Czetwertyńska M, Swierniak M, Długosińska J, Maciag M, Czajka A, Dymecka K, Kubiak A, Kot A, Płoski R, de la Chapelle A, Jazdzewski K. Variants in the ATM-CHEK2-BRCA1 axis determine genetic predisposition and clinical presentation of papillary thyroid carcinoma. <i>Genes Chromosomes Cancer</i> . 2014 Jun;53(6):516-23
64.	Wojcicka A, Piekuelko-Witkowska A, Kedzierska H, Rybicka B, Poplawski P, Boguslawska J, Master A, Nauman A. Epigenetic regulation of thyroid hormone receptor beta in renal cancer. <i>PLoS One</i> . 2014 May 21;9(5):e97624.
65.	Boguslawska J, Piekuelko-Witkowska A, Wojcicka A, Kedzierska H, Poplawski P, Nauman A. Regulatory feedback loop between T3 and microRNAs in renal cancer. <i>Mol Cell Endocrinol</i> . 2014 Mar 25;384(1-2):61-70.
66.	Wojcicka A, de la Chapelle A, Jazdzewski K. MicroRNA-related sequence variations in human cancers. <i>Hum Genet</i> . 2014 Apr;133(4):463-9
67.	Piekutowska-Abramczuk D, Pronicki M, Strawa K, Karkucińska-Więckowska A, Szymańska-Dębińska T, Fidziańska A, Więckowski MR, Jurkiewicz D, Ciara E, Jankowska I, Sykut-Cegielska J, Krajewska-Walasek M, Płoski R, Pronicka E. Novel c.191C>G (p.Pro64Arg) MPV17 mutation identified in two pairs of unrelated Polish siblings with mitochondrial hepatoencephalopathy. <i>Clin Genet</i> . 2014 Jun;85(6):573-7.
68.	Kostera-Pruszczyk A, Kosinska J, Pollak A, Stawinski P, Walczak A, Wasilewska K, Potulska-Chromik A, Szczudlik P, Kaminska A, Ploski R. Exome sequencing reveals mutations in MFN2 and GDAP1 in severe Charcot-Marie-Tooth disease. <i>J Peripher Nerv Syst</i> . 2014 Sep;19(3):242-5.
69.	Ploski R, Pollak A, Müller S, Franaszczyk M, Michalak E, Kosinska J, Stawinski P,



	Spiewak M, Seggewiss H, Bilinska ZT. Does p.Q247X in TRIM63 cause human hypertrophic cardiomyopathy? <i>Circ Res.</i> 2014 Jan 17;114(2):e2-5
70.	Szymanska S, Rokicki D, Karkucinska-Wieckowska A, Szymanska-Debinska T, Ciara E, Ploski R, Grajkowska W, Pronicki M. Case report of an adolescent girl with limb-girdle muscular dystrophy type 2B - the usefulness of muscle protein immunostaining in the diagnosis of dysferlinopathies. <i>Folia Neuropathol.</i> 2014;52(4):452-6.
71.	Ziarkiewicz-Wróblewska B, Sajjad E, Cizek M, Hutnik L, Lukasik D, Fedorowicz M, Wróblewski T, Patkowski W, Pączek L, Płoski R, Włodarski P, Malejczyk J. Association of 49245A>G (rs868) Polymorphism in the 3'UTR of Donor TGFBR1 Gene with Course of Hepatitis C following Orthotopic Liver Transplantation. <i>Ann Transplant.</i> 2014 Dec 12;19:643-51.
72.	Kalinska-Bienias A, Kostrzewa G, Malejczyk M, Ploski R, Majewski S. Possible association between actinic keratosis and the rs7208422 (c.917A→T, p.N306I) polymorphism of the EVER2 gene in patients without epidermodysplasia verruciformis. <i>Clin Exp Dermatol.</i> 2014 Dec 12. doi: 10.1111/ced.12506.
73.	Cottenie E, Kochanski A, Jordanova A, Bansagi B, Zimon M, Horga A, Jaunmuktane Z, Saveri P, Rasic VM, Baets J, Bartsakoulia M, Ploski R, Teterycz P, Nikolic M, Quinlivan R, Laura M, Sweeney MG, Taroni F, Lunn MP, Moroni I, Gonzalez M, Hanna MG, Bettencourt C, Chabrol E, Franke A, von Au K, Schilhabel M, Kabzińska D, Hausmanowa-Petrusewicz I, Brandner S, Lim SC, Song H, Choi BO, Horvath R, Chung KW, Zuchner S, Pareyson D, Harms M, Reilly MM, Houlden H. Truncating and missense mutations in IGHMBP2 cause Charcot-Marie Tooth disease type 2. <i>Am J Hum Genet.</i> 2014 Nov 6;95(5):590-601.
74.	Pazik J, Ołdak M, Lewandowski Z, Dąbrowski M, Podgórska M, Sitarek E, Malejczyk J, Płoski R, Durlik M. Recipient uridine 5'-diphosphoglucuronosyltransferase UGT1A9 c.98T>C variant determines transplanted kidney filtration rate. <i>Transplant Proc.</i> 2014 Oct;46(8):2678-82.
75.	Ołdak M, Ruszkowska E, Pollak A, Sobczyk-Kopcioł A, Kowalewski C, Piwońska A, Drygas W, Płoski R. A note of caution on the diagnosis of Martin-Probst syndrome by the detection of the p.D59G mutation in the RAB40AL gene. <i>Eur J Pediatr.</i> 2014 Nov 5.
76.	Chojnicka I, Fudalej S, Walczak A, Wasilewska K, Fudalej M, Stawiński P, Strawa K, Pawlak A, Wojnar M, Krajewski P, Płoski R. Inverse association between obesity predisposing FTO genotype and completed suicide. <i>PLoS One.</i> 2014 Sep 29;9(9):e108900.
77.	Pawlak A, Pronicki M, Iwanicka-Pronicka K, Kuśnierz J, Ploski R, Pollak A, Gil RJ. Cardiological manifestation of MELAS syndrome associated with mutation at position 3234. <i>Kardiologia Polska.</i> 2014;72(1):83.
78.	Bukowska-Ośko I, Caraballo Cortés K, Pawełczyk A, Płoski R, Fic M, Perlejewski K, Demkow U, Berak H, Horban A, Laskus T, Radkowski M. Analysis of genotype 1b hepatitis C virus IRES in serum and peripheral blood mononuclear cells in patients treated with interferon and ribavirin. <i>Biomed Res Int.</i> 2014;2014:175405.
79.	Nehring P, Mrozikiewicz-Rakowska B, Krzyżewska M, Sobczyk-Kopcioł A, Płoski R, Broda G, Karnafel W. Diabetic foot risk factors in type 2 diabetes patients: a cross-sectional case control study. <i>J Diabetes Metab Disord.</i> 2014 Aug 4;13:79.
80.	Szpakowicz A, Kiliszek M, Pepinski W, Waszkiewicz E, Franaszczyk M, Skawronska M, Ploski R, Niemcunowicz-Janica A, Dobrzycki S, Opolski G, Musiał



	WJ, Kaminski KA. Polymorphism of 9p21.3 locus is associated with 5-year survival in high-risk patients with myocardial infarction. <i>PLoS One</i> . 2014 Aug 8;9(8):e104635.
81.	Pamjav H, Volgyi A, Barany G, Pawlowski R, Maciejewska A, Pelotti S, Pepinski W, Abreu-Glowacka M, Phillips C, Cárdenas J, Rey-Gonzalez D, Salas A, Brisighelli F, Capelli C, Toscanini U, Piccinini A, Piglionica M, Baldassarra SL, Ploski R, Konarzewska M, Jastrzebska E, Robino C, Sajantila A, Palo JU, Guevara E, Salvador J, Ungria MC, Rodriguez JJ, Schmidt U, Schlauderer N, Saukko P, Schneider PM, Sirker M, Shin KJ, Oh YN, Skitsa I, Ampati A, Smith TG, Calvit LS, Stenzl V, Capal T, Tillmar A, Nilsson H, Turrina S, De Leo D, Verzeletti A, Cortellini V, Wetton JH, Gwynne GM, Jobling MA, Whittle MR, Sumita DR, Wolańska-Nowak P, Yong RY, Krawczak M, Nothnagel M, Roewer L. A global analysis of Y-chromosomal haplotype diversity for 23 STR loci. <i>Forensic Sci Int Genet</i> . 2014 Sep;12:12-23.
82.	Jurecka-Lubieniecka B, Ploski R, Kula D, Szymanski K, Bednarczuk T, Ambroziak U, Hasse-Lazar K, Hyla-Klekot L, Tukiendorf A, Kolosza Z, Jarzab B. Association between polymorphisms in the TSHR gene and Graves' orbitopathy. <i>PLoS One</i> . 2014 Jul 25;9(7):e102653.
83.	Óldak M, Ścieżyńska A, Młynarski W, Borowiec M, Ruszkowska E, Szulborski K, Pollak A, Kosińska J, Mueller-Malesińska M, Stawiński P, Szaflik JP, Płoski R. Evidence against RAB40AL being the locus for Martin-Probst X-linked deafness-intellectual disability syndrome. <i>Hum Mutat</i> . 2014 Oct;35(10):1171-4.
84.	Cortés KC, Zagordi O, Perlejewski K, Laskus T, Maroszek K, Bukowska-Oško I, Pawelczyk A, Płoski R, Berak H, Horban A, Radkowski M. Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcome. <i>BMC Infect Dis</i> . 2014 Jul 13;14:389.
85.	Franaszczyk M, Bilinska ZT, Sobieszcańska-Małek M, Michalak E, Sleszycka J, Sioma A, Małek ŁA, Kaczmarek D, Walczak E, Włodarski P, Hutnik Ł, Milanowska B, Dzielinska Z, Religa G, Grzybowski J, Zieliński T, Ploski R. The BAG3 gene variants in Polish patients with dilated cardiomyopathy: four novel mutations and a genotype-phenotype correlation. <i>J Transl Med</i> . 2014 Jul 9;12:192.
86.	Ballantyne KN, Ralf A, Aboukhalid R, Achakzai NM, Anjos MJ, Ayub Q, Balažić J, Ballantyne J, Ballard DJ, Berger B, Bobillo C, Bouabdellah M, Burri H, Capal T, Caratti S, Cárdenas J, Cartault F, Carvalho EF, Carvalho M, Cheng B, Coble MD, Comas D, Corach D, D'Amato ME, Davison S, de Knijff P, De Ungria MC, Decorte R, Dobosz T, Dupuy BM, Elmrghni S, Gliwiński M, Gomes SC, Grol L, Haas C, Hanson E, Henke J, Henke L, Herrera-Rodríguez F, Hill CR, Holmlund G, Honda K, Immel UD, Inokuchi S, Jobling MA, Kaddura M, Kim JS, Kim SH, Kim W, King TE, Klausriegler E, Kling D, Kovačević L, Kovatsi L, Krajewski P, Kravchenko S, Larmuseau MH, Lee EY, Lessig R, Livshits LA, Marjanović D, Minarik M, Mizuno N, Moreira H, Morling N, Mukherjee M, Munier P, Nagaraju J, Neuhuber F, Nie S, Nilasitsatporn P, Nishi T, Oh HH, Olofsson J, Onofri V, Palo JU, Pamjav H, Parson W, Petlach M, Phillips C, Ploski R, Prasad SP, Primorac D, Purnomo GA, Purps J, Rangel-Villalobos H, Rębała K, Rerkamnuaychoke B, Gonzalez DR, Robino C, Roewer L, Rosa A, Sajantila A, Sala A, Salvador JM, Sanz P, Schmitt C, Sharma AK, Silva DA, Shin KJ, Sijen T, Sirker M, Siváková D, Skaro V, Solano-Matamoros C, Souto L, Stenzl V, Sudoyo H, Syndercombe-Court D, Tagliabracci A, Taylor D, Tillmar A, Tsybovsky IS, Tyler-Smith C, van der Gaag



	KJ, Vanek D, Völgyi A, Ward D, Willemse P, Yap EP, Yong RY, Pajnič IZ, Kayser M. Toward male individualization with rapidly mutating y-chromosomal short tandem repeats. <i>Hum Mutat.</i> 2014 Aug;35(8):1021-32.
87.	Purps J, Siegert S, Willuweit S, Nagy M, Alves C, Salazar R, Angustia SM, Santos LH, Anslinger K, Bayer B, Ayub Q, Wei W, Xue Y, Tyler-Smith C, Bafalluy MB, Martínez-Jarreta B, Egyed B, Balitzki B, Tschumi S, Ballard D, Court DS, Barrantes X, Bäßler G, Wiest T, Berger B, Niederstätter H, Parson W, Davis C, Budowle B, Burri H, Borer U, Koller C, Carvalho EF, Domingues PM, Chamoun WT, Coble MD, Hill CR, Corach D, Caputo M, D'Amato ME, Davison S, Decorte R, Larmuseau MH, Ottoni C, Rickards O, Lu D, Jiang C, Dobosz T, Jonkisz A, Frank WE, Furac I, Gehrig C, Castella V, Grskovic B, Haas C, Wobst J, Hadzic G, Drobnic K, Honda K, Hou Y, Zhou D, Li Y, Hu S, Chen S, Immel UD, Lessig R, Jakovski Z, Ilievska T, Klann AE, García CC, de Knijff P, Kraaijenbrink T, Kondili A, Miniati P, Vouropoulou M, Kovacevic L, Marjanovic D, Lindner I, Mansour I, Al-Azem M, Andari AE, Marino M, Furfuro S, Locarno L, Martín P, Luque GM, Alonso A, Miranda LS, Moreira H, Mizuno N, Iwashima Y, Neto RS, Nogueira TL, Silva R, Nastainczyk-Wulf M, Edelmann J, Kohl M, Nie S, Wang X, Cheng B, Núñez C, Pancorbo MM, Olofsson JK, Morling N, Onofri V, Tagliabracci A, Tesson F, Saj M, Uvaize MM, Nicolas H, Płoski R, Bilińska Z. Lamin A/C mutations in dilated cardiomyopathy. <i>Cardiol J.</i> 2014;21(4):331-42.
88.	Strawa K, Markowska A, Miśkiewicz P, Kuś A, Ambroziak U, Szymański K, Zbiec R, Spólnicka M, Krajewski P, Bednarczuk T, Płoski R. Increased concentration of T-cell receptor rearrangement excision circles (TREC) in peripheral blood in Graves' disease. <i>Clin Endocrinol (Oxf).</i> 2014 Nov;81(5):769-74.
89.	Bukowska-Ośko I, Radkowski M, Pawełczyk A, Rosinska M, Caraballo C.K, Płoski R, Berak H, Horoban A, Stanczak J, Fic M, Laskus T. Hepatitis C virus 5' untranslated region variability correlates with treatment outcome. <i>J Viral Hepat.</i> 2014 Aug;21(8):551-9.
90.	Soltyszewski I, Pepinski W, Wolanska-Nowak P, Maciejewska A, Paszkowska R, Abreu-Glowacka M, Achrem W, Jonkisz A, Lebioda A, Konarzewska M, Płoski R. Polish population data on 15 autosomal STRs of AmpFISTR NGM PCR kit. <i>Forensic Sci Int Genet.</i> 2014 Mar;9:142-9.
91.	Oldak M, Szaflik JP, Ścieżyńska A, Udziela M, Maksym RB, Rymgayłło-Jankowska B, Hofmann-Rummelt C, Menzel-Severing J, Płoski R, Żarnowski T, Kruse FE, Szaflik J. Late-onset lattice corneal dystrophy without typical lattice lines caused by a novel mutation in the TGFBI gene. <i>Cornea.</i> 2014 Mar;33(3):294-9
92.	Szymański K, Miśkiewicz P, Pirko K, Jurecka-Lubieniecka B, Kula D, Hasse-Lazar K, Krajewski P, Bednarczuk T, Płoski R. rs3827440, a nonsynonymous single nucleotide polymorphism within GPR174 gene in X chromosome, is associated with Graves' disease in Polish Caucasian population. <i>Tissue Antigens.</i> 2014 Jan;83(1):41-4.
93.	Nehring P, Mrozikiewicz-Rakowska B, Maroszek P, Sobczyk-Kopciół A, Krzyżewska M, Płoski R, Karnafel W. Risk factors of charcot neuroarthropathy development in patients with type 2 diabetes. <i>Exp Clin Endocrinol Diabetes.</i> 2014 Jan;122(1):31-4
94.	Winiarska M, Bojarczuk K, Pyrzyńska B, Bil J, Siernicka M, Dwojak M, Bobrowicz M, Miazek N, Zapala P, Zagozdzon A, Krol M, Syta A, Podrzywałow-Bartnicka P, Pilch Z, Dabrowska-Iwanicka A, Juszczyński P, Efremov DG, Ślabicki M, Zenz T,



	Roy AL, Olive D, Rygiel TP, Leusen JH, Golab J. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. <i>MAbs</i> . 2014 Sep 3;6(5):1300-13.
95.	Muchowicz A, Firczuk M, Chlebowska J, Nowis D, Stachura J, Barankiewicz J, Trzeciecka A, Kłossowski S, Ostaszewski R, Zagozdżon R, Pu JX, Sun HD, Golab J. Adenanthin targets proteins involved in the regulation of disulphide bonds. <i>Biochem Pharmacol</i> . 2014 May 15;89(2):210-6.
96.	Nowis D, Malenda A, Furs K, Oleszczak B, Sadowski R, Chlebowska J, Firczuk M, Bujnicki JM, Staruch AD, Zagozdżon R, Glodkowska-Mrowka E, Szablewski L, Golab J. Statins impair glucose uptake in human cells. <i>BMJ Open Diabetes Res Care</i> . 2014 Apr 26;2(1):e000017.
97.	Bojarczuk K, Siernicka M, Dwojak M, Bobrowicz M, Pyrzynska B, Gaj P, Karp M, Giannopoulos K, Efremov DG, Fauriat C, Golab J, Winiarska M. B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. <i>Leukemia</i> . 2014 May;28(5):1163-7.
98.	Zerrouqi A, Pyrzynska B, Brat DJ, Van Meir EG. P14ARF suppresses tumor-induced thrombosis by regulating the tissue factor pathway. <i>Cancer Res</i> . 2014 Mar 1;74(5):1371-8.
99.	Gaj P, Zagozdżon R. In silico analysis of microRNA-510 as a potential oncomir in human breast cancer. <i>Breast Cancer Res</i> . 2014;16(2):403.
100.	Gil J, Gaj P, Misiak B, Ostrowski J, Karpinski P, Jarczyńska A, Kielan W, Sasiadek MM. CYP1A1 Ile462Val polymorphism and colorectal cancer risk in Polish patients. <i>Med Oncol</i> . 2014 Jul;31(7):72.
101.	Noreen F, Rössli M, Gaj P, Pietrzak J, Weis S, Urfer P, Regula J, Schär P, Truninger K. Modulation of age- and cancer-associated DNA methylation change in the healthy colon by aspirin and lifestyle. <i>J Natl Cancer Inst</i> . 2014 Jun 28;106(7).
102.	O'Leary PC, Terrile M, Bajor M, Gaj P, Hennessy BT, Mills GB, Zagozdżon A, O'Connor DP, Brennan DJ, Connor K, Li J, Gonzalez-Angulo AM, Sun HD, Pu JX, Pontén F, Uhlén M, Jirström K, Nowis DA, Crown JP, Zagozdżon R, Gallagher WM. Peroxiredoxin-1 protects estrogen receptor $\alpha$ from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer. <i>Breast Cancer Res</i> . 2014 Jul 10;16(4):R79.
103.	Mucha K, Bakun M, Jaźwiec R, Dadlez M, Florczak M, Bajor M, Gala K, Pączek L. Complement components, proteolysis-related, and cell communication-related proteins detected in urine proteomics are associated with IgA nephropathy. <i>Pol Arch Med Wewn</i> . 2014 Aug 7;124(7-8):380-6
104.	Lasek W, Zagozdżon R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? <i>Cancer Immunol Immunother</i> . 2014 May;63(5):419-35.
105.	Burdzinska A, Gala K, Kowalewski C, Zagozdżon R, Gajewski Z, Pączek L. Dynamics of acute local inflammatory response after autologous transplantation of muscle-derived cells into the skeletal muscle. <i>Mediators Inflamm</i> . 2014;2014:482352.
106.	Młynarczuk-Biały I, Doepfner TR, Golab J, Nowis D, Wilczynski GM, Parobczak K, Wigand ME, Hajdamowicz M, Biały LP, Aniolek O, Henklein P, Bähr M, Schmidt B, Kuckelkorn U, Kloetzel PM. Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model. <i>Transl Oncol</i> . 2014 Oct 24;7(5):570-9.
107.	Serda M, Kalinowski DS, Rasko N, Potůčková E, Mrozek-Wilczkiewicz A, Musiol



	R, Małeckı JG, Sajewicz M, Ratuszna A, Muchowicz A, Golab J, Simůnek T, Richardson DR, Polanski J. Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships. PLoS One. 2014 Oct 16;9(10):e110291.
108.	Wachowska M, Gabrysiak M, Golab J. Epigenetic remodeling combined with photodynamic therapy elicits anticancer immune responses. Oncoimmunology. 2014 May 15;3:e28837.
109.	Mrozek-Wilczkiewicz A, Serda M, Musiol R, Małeckı G, Szurko A, Muchowicz A, Golab J, Ratuszna A, Polanski J. Iron chelators in photodynamic therapy revisited: synergistic effect by novel highly active thiosemicarbazones. ACS Med Chem Lett. 2014 Jan 23;5(4):336-9.
110.	Glodkowska-Mrowka E, Mrowka P, Basak GW, Niesiobedzka-Krezel J, Seferynska I, Włodarski PK, Jakobisiak M, Stokłosa T. Statins inhibit ABCB1 and ABCG2 drug transporters activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib. Exp Hematol. 2014 Jun;42(6):439-4
111.	Machnicki MM, Stokłosa T. BRAF - A new player in hematological neoplasms. Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):77-83
112.	Kilarski WW, Muchowicz A, Wachowska M, Mężyk-Kopeć R, Golab J, Swartz MA, Nowak-Sliwinska P. Optimization and regeneration kinetics of lymphatic-specific photodynamic therapy in the mouse dermis. Angiogenesis. 2014 Apr;17(2):347-57.
113.	Wachowska M, Gabrysiak M, Muchowicz A, Bednarek W, Barankiewicz J, Rygiel T, Boon L, Mroz P, Hamblin MR, Golab J. 5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy. Eur J Cancer. 2014 May;50(7):1370-81.
114.	Taher C, Frisk G, Fuentes S, Religa P, Costa H, Assinger A, Vetvik KK, Bukholm IR, Yaiw KC, Smedby KE, Bäcklund M, Söderberg-Naucler C, Rahbar A. High prevalence of human cytomegalovirus in brain metastases of patients with primary breast and colorectal cancers. Transl Oncol. 2014 Dec;7(6):732-40.
115.	Kurzejamska E, Johansson J, Jirström K, Prakash V, Ananthaseshan S, Boon L, Fuxe J, Religa P. C/EBP $\beta$ expression is an independent predictor of overall survival in breast cancer patients by MHCII/CD4-dependent mechanism of metastasis formation. Oncogenesis. 2014 Nov 3;3:e125.
116.	Cermakova P, Eriksson M, Lund LH, Winblad B, Religa P, Religa D. Heart failure and Alzheimer's disease. J Intern Med. 2015 Apr;277(4):406-25.
117.	Butler LM, Dzabic M, Bakker F, Davoudi B, Jeffery H, Religa P, Bojakowski K, Yaiw KC, Rahbar A, Söderberg-Naucler C. Human Cytomegalovirus Inhibits Erythropoietin Production. J Am Soc Nephrol. 2014 Aug;25(8):1669-78
118.	Assinger A, Kral JB, Yaiw KC, Schrottmaier WC, Kurzejamska E, Wang Y, Mohammad AA, Religa P, Rahbar A, Schabbauer G, Butler LM, Söderberg-Naucler C. Human cytomegalovirus-platelet interaction triggers toll-like receptor 2-dependent proinflammatory and proangiogenic responses. Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):801-9
119.	Yaiw KC, Mohammad AA, Taher C, Wilhelmi V, Davoudi B, Strååt K, Assinger A, Ovchinnikova O, Shlyakhto E, Rahbar A, Kovtonyuk O, Religa P, Butler L, Khan Z, Streblow D, Pernow J, Söderberg-Naucler C. Human cytomegalovirus induces upregulation of arginase II: possible implications for vasculopathies. Basic Res



	Cardiol. 2014 Mar;109(2):401.
120.	Graham S, et al. incl. Gaciong Z among 253 co-authors. Cognitive function in ambulatory patients with systolic heart failure: insights from the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial. PLoS One. 2014 Nov 26;9(11):e113447.
121.	Lewandowski J, Siński M, Puchalska L, Symonides B, Gaciong Z. Simvastatin but not ezetimibe reduces sympathetic activity despite similar reductions in cholesterol levels. J Am Soc Hypertens. 2014 Oct;8(10):715-23.
122.	Pullicino PM, et al. incl. Gaciong Z among >500 co-authors. Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial. Cerebrovasc Dis. 2014;38(3):176-81.
123.	Rutkowski M, Bandosz P, Czupryniak L, Gaciong Z, Solnica B, Jasiel-Wojculewicz H, Wyrzykowski B, Pencina MJ, Zdrojewski T. Prevalence of diabetes and impaired fasting glucose in Poland--the NATPOL 2011 Study. Diabet Med. 2014 Dec;31(12):1568-71.
124.	Halperin JL, et al. incl. Gaciong Z among >1000 co-authors.. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014 Jul 8;130(2):138-46.
125.	Orłowska-Baranowska E, Gora J, Baranowski R, Stokłosa P, Gadomska vel Betka L, Pedzich-Placha E, Milkowska M, Koblowska MK, Hryniewiecki T, Gaciong Z, Placha G. Association of the common genetic polymorphisms and haplotypes of the chymase gene with left ventricular mass in male patients with symptomatic aortic stenosis. PLoS One. 2014 May 13;9(5):e96306.
126.	Sinski M, Lewandowski J, Przybylski J, Zalewski P, Symonides B, Abramczyk P, Gaciong Z. Deactivation of carotid body chemoreceptors by hyperoxia decreases blood pressure in hypertensive patients. Hypertens Res. 2014 Sep;37(9):858-62.
127.	Symonides B, Holas P, Schram M, Śleszycka J, Bogaczewicz A, Gaciong Z. Does the control of negative emotions influence blood pressure control and its variability? Blood Press. 2014 Dec;23(6):323-9.
128.	Meyer G, et al. incl. Gaciong Z among 129 co-authors. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014 Apr 10;370(15):1402-11.
129.	Schulman S, et al. incl. Gaciong Z among >232 co-authors. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014 Feb 18;129(7):764-72
130.	Młynarczyk-Bonikowska B, Kujawa M, Młynarczyk G, Malejczyk M, Majewski S. [Resistance to ciprofloxacin of Neisseria gonorrhoeae strains isolated in Poland in 2012-2013]. Med Dosw Mikrobiol. 2014;66(2):99-104.
131.	Foronczewicz B, Mucha K, Lerut J, Majewski S, Krawczyk M, Pączek L. Cyclosporine is superior to tacrolimus in liver transplant recipients with recurrent psoriasis. Ann Transplant. 2014 Aug 28;19:427-33.
132.	Grąt M, Grąt K, Hołówko W, Malejczyk M, Walter de Walthoffen S, Lewandowski Z, Kobryń K, Patkowski W, Majewski S, Młynarczyk G, Krawczyk M. Initial prevalence of anal human papilloma virus infection in liver transplant recipients. Transpl Int. 2014 Aug;27(8):816-23.
133.	Młynarczyk-Bonikowska B, Serwin AB, Golparian D, Walter de Walthoffen S,



	Majewski S, Koper M, Malejczyk M, Domeika M, Unemo M. Antimicrobial susceptibility/resistance and genetic characteristics of <i>Neisseria gonorrhoeae</i> isolates from Poland, 2010-2012. <i>BMC Infect Dis.</i> 2014 Feb 6;14:65.
134.	Terlikowska-Brzósko A, Paluchowska E, Owczarek W, Majewski S. Papuloerythroderma of Ofuji in a 41-year-old woman. <i>Postepy Dermatol Alergol.</i> 2013 Oct;30(5):324-8
135.	Garg AD, Martin S, Golab J, Agostinis P. Danger signalling during cancer cell death: origins, plasticity and regulation. <i>Cell Death Differ.</i> 2014 Jan;21(1):26-38
136.	Kuś A, Szymański K, Peeters RP, Miśkiewicz P, Porcu E, Pistis G, Sanna S, Naitza S, Płoski R, Medici M, Bednarczuk T. The association of thyroid peroxidase antibody risk loci with susceptibility to and phenotype of Graves' disease. <i>Clin Endocrinol (Oxf).</i> 2014 (in press).
137.	Szpakowicz A, Kiliszek M, Pepiński W, Waszkiewicz E, Franaszczyk M, Skawrońska M, Dobrzycki S, Niemcunowicz-Janica A, Ploski R, Opolski G, Musiał WJ, Kamiński KA. The rs9982601 polymorphism of the region between the SLC5A3/MRPS6 and KCNE2 genes associated with a prevalence of myocardial infarction and subsequent long-term mortality. <i>Pol Arch Med Wewn.</i> 2015;125:240-248.
138.	Ormerod AD, van Voorst Vader PC, Majewski S, Vanscheidt W, Benjamin N, van der Meijden W. Evaluation of the Efficacy, Safety, and Tolerability of 3 Dose Regimens of Topical Sodium Nitrite With Citric Acid in Patients With Anogenital Warts: A Randomized Clinical Trial. <i>JAMA Dermatol.</i> 2015;151:854-861.
139.	Dudek-Peric AM, Garg A, Golab J, Agostinis A. Melanoma targeting with the (loco-) regional chemotherapeutic, Melphalan: from cell death to immunogenic efficacy <i>Oncoimmunology</i> 2015 (in press).
140.	Wachowska M, Muchowicz A, Golab J. Targeting epigenetic processes in photodynamic therapy-induced anticancer immunity. <i>Front Immunol</i> 2015; 5:176. doi: 10.3389/fonc.2015.00176
141.	Sajjad EA, Sikora K, Paciejewski T, Garbicz F, Paskal W, Szacht M, Grajkowska W, Włodarski PK. Intraparenchymal mesenchymal chondrosarcoma of the frontal lobe - a case report and molecular detection of specific gene fusions from archival FFPE sample. <i>Clin Neuropathol.</i> 2015 Sep-Oct;34(5):288-93
142.	Gharagozloo M, Majewski S, Foldvari M. Therapeutic applications of nanomedicine in autoimmune diseases: From immunosuppression to tolerance induction. <i>Nanomedicine.</i> 2015;11:1003-1018.
143.	Ratz-Łyko A, Arct J, Majewski S, Pytkowska K. Influence of Polyphenols on the Physiological Processes in the Skin. <i>Phytother Res.</i> 201529:509-517.
144.	Banach-Orłowska M, Szymanska E, Miaczynska M. APPL1 endocytic adaptor as a fine tuner of Dvl2-induced transcription. <i>FEBS Lett.</i> 2015 Feb 13;589(4):532-9
145.	Kostera-Pruszczyk A, Potulska-Chromik A, Pruszczyk P, Bieganska K, Miszczak-Knecht M, Bienias P, Szczaluba K, Lee HY, Quinn E, Ploski R, Kaminska A, Ptáček LJ. Andersen-Tawil syndrome: Report of 3 novel mutations and high risk of symptomatic cardiac involvement. <i>Muscle Nerve.</i> 2015 Feb;51(2):192-6
146.	Wortmann SB, Ziętkiewicz S, Kousi M, Szklarczyk R, Haack TB, Gersting SW, Muntau AC, Rakovic A, Renkema GH, Rodenburg RJ, Strom TM, Meitinger T, Rubio-Gozalbo ME, Chrusciel E, Distelmaier F, Golzio C, Jansen JH, van Karnebeek C, Lillquist Y, Lücke T, Öunap K, Zordania R, Yapliito-Lee J, van





	Bokhoven H, Spelbrink JN, Vaz FM, Pras-Raves M, Ploski R, Pronicka E, Klein C, Willemsen MA, de Brouwer AP, Prokisch H, Katsanis N, Wevers RA. CLPB Mutations Cause 3-Methylglutaconic Aciduria, Progressive Brain Atrophy, Intellectual Disability, Congenital Neutropenia, Cataracts, Movement Disorder. <i>Am J Hum Genet.</i> 2015 Feb 5;96(2):245-257.
147.	Zbieć-Piekarska R, Spólnicka M, Kupiec T, Makowska Ż, Spas A, Parys-Proszek A, Kucharczyk K, Płoski R, Branicki W. Examination of DNA methylation status of the ELOVL2 marker may be useful for human age prediction in forensic science. <i>Forensic Sci Int Genet.</i> 2015 Jan;14:161-7.
148.	Bukowska-Ośko I, Pawełczyk A, Perlejewski K, Kubisa N, Caraballo Cortés K, Rosińska M, Płoski R, Fic M, Kaźmierczak J, Popiel M, Ząbek P, Horban A, Radkowski M, Laskus T. Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin. <i>PLoS One.</i> 2015 May 1;10(5):e0125604
149.	Truszkowska GT, Bilińska ZT, Kosińska J, Śleszycka J, Rydzanicz M, Sobieszczkańska-Małek M, Franaszczyk M, Bilińska M, Stawiński P, Michalak E, Małek ŁA, Chmielewski P, Foss-Nieradko B, Machnicki MM, Stokłosa T, Ponińska J, Szumowski Ł, Grzybowski J, Piwoński J, Drygas W, Zieliński T, Płoski R. A study in Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutations. <i>BMC Med Genet.</i> 2015 Apr 3;16(1):21.
150.	Nehring P, Makowski A, Mrozikiewicz-Rakowska B, Sobczyk-Kopciół A, Płoski R, Karnafel W. Risk factors of diabetic foot of neuropathic origin in patients with type 2 diabetes. <i>Endokrynol Pol.</i> 2015;66(1):10-4.
151.	Iwanicka-Pronicka K, Pollak A, Skórka A, Lechowicz U, Korniszewski L, Westfal P, Skarżyński H, Płoski R. Audio profiles in mitochondrial deafness m.1555A>G and m.3243A>G show distinct differences. <i>Med Sci Monit.</i> 2015 Mar 6;21:694-700.
152.	Nowak I, Płoski R, Barcz E, Dziunycz P, Kamiński P, Kostrzewa G, Milewski Ł, Roszkowski PI, Senitzer D, Malejczyk J, Kuśnierczyk P. KIR2DS5 in the presence of HLA-C C2 protects against endometriosis. <i>Immunogenetics.</i> 2015 Apr;67(4):203-9.
153.	Zbieć-Piekarska R, Spólnicka M, Kupiec T, Parys-Proszek A, Makowska Ż, Pałeczka A, Kucharczyk K, Płoski R, Branicki W. Development of a forensically useful age prediction method based on DNA methylation analysis. <i>Forensic science international. Genetics.</i> 2015 Jul;17:173-9.
154.	Kisiel B, Kruszewski R, Juskiewicz A, Raczkiewicz A, Bachta A, Kłos K, Duda K, Saracyn M, Szymański K, Młozniak-Cieśla A, Grabowska-Jodkowska A, Olesińska M, Bogusławska-Walecka R, Niemczyk S, Płoski R, Thustochowicz W. Systemic lupus erythematosus: the influence of disease-related and classical risk factors on intima media thickness and prevalence of atherosclerotic plaques--a preliminary report. Beneficial effect of immunosuppressive treatment on carotid intima media thickness. <i>Acta Cardiologica.</i> 2015 Apr;70(2):169-75.
155.	Óldak M, Ruszkowska E, Pollak A, Sobczyk-Kopciół A, Kowalewski C, Piwońska A, Drygas W, Płoski R. A note of caution on the diagnosis of Martin-Probst syndrome by the detection of the p.D59G mutation in the RAB40AL gene. <i>Eur J Pediatrics.</i> 2015 May;174(5):693-6.
156.	Kostera-Pruszczyk A, Potulska-Chromik A, Pruszczyk P, Bieganowska K, Miszczak-Knecht M, Bienias P, Szczałuba K, Lee HY, Quinn E, Ploski R,



	Kaminska A, Ptáček LJ. Andersen-Tawil syndrome: report of 3 novel mutations and high risk of symptomatic cardiac involvement. <i>Muscle &amp; Nerve</i> . 2015 Feb;51(2):192-6.
157.	Kisiel B, Kruszewski R, Juszkiewicz A, Raczekiewicz A, Bachtá A, Tłustochowicz M, Staniszevska-Varga J, Kłos K, Duda K, Bogusławska-Walecka R, Płoski R, Tłustochowicz W. Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis. <i>J Immunol Res</i> . 2015;2015:759610.
158.	Szpakowicz A, Kiliszek M, Pepinski W, Waszkiewicz E, Franaszczyk M, Skawronska M, Ploski R, Niemcunowicz-Janica A, Burzynska B, Tulacz D, Maciejak A, Kaminski MJ, Opolski G, Musial WJ, Kaminski KA. The rs12526453 Polymorphism in an Intron of the PHACTR1 Gene and Its Association with 5-Year Mortality of Patients with Myocardial Infarction. <i>PLoS One</i> . 2015 Jun 18;10(6):e0129820
159.	Prochenka A, Pokarowski P, Gasperowicz P, Kosińska J, Stawiński P, Zbieć-Piekarska R, Spólnicka M, Branicki W, Płoski R. A cautionary note on using binary calls for analysis of DNA methylation. <i>Bioinformatics</i> . 2015 May 1;31(9):1519-20.
160.	Kalinska-Bienias A, Kostrzewa G, Malejczyk M, Ploski R, Majewski S. Possible association between actinic keratosis and the rs7208422 (c.917A→T, p.N306I) polymorphism of the EVER2 gene in patients without epidermodysplasia verruciformis. <i>Clin Exp Dermatol</i> . 2015 Apr;40(3):318-23
161.	Muchowicz A, Firczuk M, Wachowska M, Kujawa M, Jankowska-Steifer E, Gabrysiak M, Pilch Z, Kłossowski S, Ostaszewski R, Golab J. SK053 triggers tumor cells apoptosis by oxidative stress-mediated endoplasmic reticulum stress. <i>Biochem Pharmacol</i> . 2015 Feb 15;93(4):418-27.
162.	Dwojak M, Bobrowicz M, Bil J, Bojarczuk K, Pyrzynska B, Siernicka M, Malenda A, Lech-Maranda E, Tomczak W, Giannopoulos K, Golab J, Winiarska M. Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins. <i>Blood Cancer J</i> . 2015 Apr 10;5:e300.
163.	Dudek-Perić AM, Ferreira GB, Muchowicz A, Wouters J, Prada N, Martin S, Kiviluoto S, Winiarska M, Boon L, Mathieu C, van den Oord J, Stas M, Gougeon ML, Golab J, Garg AD, Agostinis P. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. <i>Cancer Res</i> . 2015 Apr 15;75(8):1603-14.
164.	Zagozdzon R, Golab J. Cancer stem cells in haematological malignancies. <i>Contemp Oncol (Pozn)</i> . 2015;19(1A):A1-6.
165.	Kuzaka B, Janiak M, Włodarski KH, Radziszewski P, Włodarski PK. Expression of bone morphogenetic protein-2 and -7 in urinary bladder cancer predicts time to tumor recurrence. <i>Arch Med Sci</i> . 2015;11(2):378-84.
166.	Lewandowski J, Symonides B, Gaciong Z, Siński M. The effect of statins on sympathetic activity: a meta-analysis. <i>Clin Auton Res</i> . 2015 Apr;25(2):125-31.
167.	Majewska A, Mlynarczyk-Bonikowska B, Malejczyk M, Mlynarczyk G, Majewski S. Antiviral medication in sexually transmitted diseases. Part II: HIV. <i>Mini Rev Med Chem</i> . 2015;15(2):93-103.
168.	Ratz-Łyko A, Arct J, Majewski S, Pytkowska K. Influence of polyphenols on the physiological processes in the skin. <i>Phytother Res</i> . 2015 Apr;29(4):509-17.
169.	Ratz-Łyko A, Arct J, Pytkowska K, Majewski S. In vivo and ex vivo evaluation of cosmetic properties of seedcakes. <i>J Cosmet Laser Ther</i> . 2015 Apr;17(2):109-15.
170.	Klimczak D, Pączek L, Jażdżewski K, Kuch M. MicroRNAs: powerful regulators



	and potential diagnostic tools in cardiovascular disease. <i>Kardiol Pol.</i> 2015;73(1):1-6.
171.	Lakshmanan A, Wojcicka A, Kotlarek M, Zhang X, Jazdzewski K, Jhiang SM. MicroRNA-339-5p modulates Na <sup>+</sup> /I <sup>-</sup> symporter-mediated radioiodide uptake. <i>Endocr Relat Cancer</i> 2015;22(1):11-21
172.	Skulskal E, Młynarczyk-Bonikowska B, Walter de Walthoffen S, Młynarczyk G, Malejczyk M, Majewski S. The Comparison of Real-Time PCR and bacterial culture in laboratory diagnostics of gonorrhoea in patients of Department of Dermatology and Venereology Medical University of Warsaw. <i>Med Dosw Mikrobiol.</i> 2015;67(1):29-38
173.	Młynarczyk-Bonikowska B, Kujawa M, Młynarczyk G, Malejczyk M, Majewski S. Susceptibility of <i>Neisseria gonorrhoeae</i> strains isolated in Poland in 2012-2013 to spectinomycin. <i>Med Dosw Mikrobiol.</i> 2015;67(1):23-8
174.	Bojarczuk K, Bobrowicz M, Dwojak M, Miazek N, Zapala P, Bunes A, Siernicka M, Rozanska M, Winiarska M. B-cell receptor signaling in the pathogenesis of lymphoid malignancies. <i>Blood Cells Mol Dis.</i> 2015 Oct;55(3):255-65.
175.	Siernicka M, Winiarska M, Bajor M, Firczuk M, Muchowicz A, Bobrowicz M, Fauriat C, Golab J, Olive D, Zagodzón R. Adenanthin, a new inhibitor of thiol-dependent antioxidant enzymes, impairs the effector functions of human natural killer cells. <i>Immunology.</i> 2015 Sep;146(1):173-83.
176.	Dabek B, Kram A, Kubrak J, Kurzawski M, Wojcik P, Machnicki MM, Rydzanicz M, Debiec-Rychter M, Stokłosa T, Płoski R. A rare mutation in a rare tumor – SMARCB1-deficient malignant glomus tumor. <i>Genes, Chromosomes and Cancer</i> 2015 (in press)
177.	Wacław J, Sacha T, Stokłosa T. Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose. (Review). <i>Blood and Lymphatic Cancer: Targets and Therapy</i> 2015 (in press)
178.	Tykarski A, Narkiewicz K, Gaciong Z, Januszewicz A, Litwin M, Kostka-Jeziorny K, Adamczak M, Szczepaniak-Chicheł L, Chrostowska M, Czarnecka D, Dzida G, Filipiak KJ, Gąsowski J, Głuszek J, Grajek S, Grodzicki T, Kawecka-Jaszcz K, Wozakowska-Kapłon B, Begier-Krasińska B, Manitius J, Myśliwiec M, Niemirska A, Prejbisz A, Pupek-Musialik D, Brzezińska-Rajszys G, Stolarz-Skrzypek K, Szadkowska A, Tomasik T, Widecka K, Więcek A, Windak A, Wolf J, Zdrojewski T, Żurowska A. 2015 guidelines for the management of hypertension. Recommendations of the Polish Society of Hypertension - short version. <i>Kardiol Pol.</i> 2015;73(8):676-700.
179.	Cannon CP, et al. incl. Gaciong Z among 2574 co-authors. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <i>N Engl J Med.</i> 2015 Jun 18;372(25):2387-97.
180.	Gaciong Z. Resistant: hypertension, patient, or physician? <i>Pol Arch Med Wewn.</i> 2015;125(4):227-31.
181.	Homma S, et al. incl. Gaciong Z among 537 co-authors. Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy. <i>Circ</i>



	Heart Fail. 2015 May;8(3):504-9.
182.	Zmyslowska A, Borowiec M, Antosik K, Ploski R, Ciechanowska M, Iwaniszewska B, Jakubiuk-Tomaszuk A, Janczyk W, Krawczynski M, Salmonowicz B, Stelmach M, Mlynarski W. Genetic evaluation of patients with Alström syndrome in the Polish population. Clin Genet. 2015 (in press)

## 2.2. Posters and presentations

BASTION team leaders and newly hired researchers actively participated in 22 research conferences and showed 45 presentations (4 oral and 41 poster presentations). A list of posters and oral presentation is given below:

### Invited lectures and oral presentations:

No	Conference	Dates and location	Presentation title	Presenting researcher
1.	15th European Society for Photobiology Congress	September 3-6, 2013, Liège, Belgium	GRP79-TARGETING SUBTILASE CYTOTOXIN SENSITIZES CANCER CELLS TO PHOTODYNAMIC THERAPY	Małgorzata Firczuk (oral presentation)
2.	15th European Society for Photobiology Congress	September 3-6, 2013, Liège, Belgium	PDT-MEDIATED DAMAGE TO LYMPHATIC VESSELS – MECHANISMS AND OUTCOMES	Jakub Gołąb (invited lecture)
3.	56th American Society of Hematology Annual Meeting and Exposition	December 5-9, 2014, San Francisco, CA, USA	GENE EXPRESSION AND MUTATION ANALYSIS (GEMA) –GUIDED PRECISION MEDICINE TARGETING PARP1 TO INDUCE SYNTHETIC LETHALITY IN DNA-PK – DEFICIENT QUIESCENT AND	Tomasz Stoklosa (oral presentation)



			BRCA-DEFICIENT PROLIFERATING LEUKEMIA STEM AND PROGENITOR CELLS	
4.	International Congress of Photodynamic Applications in collaboration with European Platform for Photodynamic Medicine (EPPM) and International Photodynamic Association (IPA)	May 25-28, 2014, Dundee, UK	ANTI-LYMPHATIC EFFECTS OF PHOTODYNAMIC THERAPY AND THEIR IMPACT ON IMMUNE RESPONSE	Jakub Gołab (invited lecture)

#### Poster presentations:

No	Conference	Dates and location	Presentation title	Presenting researcher
1.	18th Congress of the European Hematology Association	June 13-17, 2013, Stockholm, Sweden	DIFFERENTIAL ACTIVATION OF MTOR KINASE IN CHRONIC AND BLASTIC PHASE OF CHRONIC MYELOGENOUS LEUKEMIA	Tomasz Stoklosa (presenting author), Eliza Glodkowska-Mrowka, Grazyna Hoser, Ilona Seferynska, Pawel Wlodarski
2.	18th Congress of the European Hematology Association	June 13-17, 2013, Stockholm, Sweden	INFLUENCE OF BCR SIGNALING PATHWAYS ON CD20 LEVELS IN TUMOR CELLS AND ACTIVITY OF ANTI-CD20 MONOCLONAL ANTIBODIES	Winiarska M (presenting author), Kamil Bojarczuk, Wanczyk M, Dwojak M, Zapala P, Miazek N, Siernicka M, Golab J.
3.	18th Congress of the European Hematology Association	June 13-17, 2013, Stockholm, Sweden	INFLUENCE OF HISTONE DEACETYLASE INHIBITORS (HDACI) ON CD20	Wanczyk M (presenting author), Kozikowski M, Dwojak M, Bojarczuk K, Golab J, Winiarska



			LEVEL AND EFFICACY OF ANTI-CD20 MONOCLONAL ANTIBODIES	M
4.	15th European Society for Photobiology Congress	September 3-6, 2013, Liège, Belgium	THE STUDY OF ANTITUMOR ACTIVITY OF THIOREDOXIN INHIBITORS AND PHOTODYNAMIC THERAPY	Angelika Muchowicz (presenting author), Szymon Klossowski, Ryszard Ostaszewski, Jakub Golab
5.	15th European Society for Photobiology Congress	September 3-6, 2013, Liège, Belgium	5-AZA-DC POTENTIATES ANTITUMOR EFFECT OF PDT IN MOUSE MODELS THROUGH THE INDUCTION OF SPECIFIC IMMUNE RESPONSE	Malgorzata Wachowska (presenting author), Magdalena Gabrysiak, Angelika Muchowicz, Joanna Barankiewicz, Tomasz Rygiel, Jakub Golab
6.	21st European Cell Death Organization Euroconference on Apoptosis	September 25 – 28, 2013, Paris, France	PDT-MEDIATED DAMAGE OF LYMPHATIC VESSELS	Malgorzata Wachowska (presenting author), Angelika Muchowicz, Witold Kilarski, Jakub Golab
7.	21st European Cell Death Organization Euroconference on Apoptosis	September 25 – 28, 2013, Paris, France	PHOTODYNAMIC THERAPY COMBINED WITH GRP78-TARGETING SUBTILASE CYTOTOXIN TRIGGER ATYPICAL CELL DEATH IN APOPTOSIS-DEFICIENT PROSTATE CANCER CELLS	Małgorzata Firczuk (presenting author)
8.	17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress	September 27 – October 1, 2013, Amsterdam, Netherlands	EPITHELIAL-MESENCHYMAL TRANSITION CONFERS RESISTANCE TO FGFR INHIBITORS	Grygielewicz P, Zdzalik D, Dymek B, Bujak A, Gunerka P, Stanczak A, Lamparska-Przybysz M, Wiczorek M,



			IN GASTRIC CANCER CELL LINE	Dzwonek K (presenting author)
9.	17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress	September 27 – October 1, 2013, Amsterdam, Netherlands	DESIGN AND DEVELOPMENT OF ACTIVE AND SELECTIVE FGFR KINASE INHIBITOR CPL-043 AS POTENTIAL ANTICANCER TARGETED THERAPY	Zdzalik D, Grygielewicz P, Lipner J, Bujak A, Dymek B, Gunerka P, Stanczak A, Lamparska- Przybysz M, Wieczorek M, Dzwonek K (presenting author)
10.	55th American Society of Hematology Annual Meeting and Exposition	December 6-10, 2013, New Orleans, LO, USA	HDAC6 INHIBITION INCREASES CD20 LEVEL AND IMPROVES THE EFFICACY OF ANTI-CD20 MONOCLONAL ANTIBODIES	Malgorzata Bobrowicz (presenting author), Michal Dwojak, Kamil Bojarczuk, Magdalena Winiarska, Jakub Golab
11.	55th American Society of Hematology Annual Meeting and Exposition	December 6-10, 2013, New Orleans, LO, USA	DIFFERENTIAL EXPRESSION OF BIRC FAMILY GENES IN THE COURSE OF CHRONIC MYELOID LEUKEMIA – BIRC3 AND BIRC8 AS POTENTIAL NEW CANDIDATES TO IDENTIFY DISEASE PROGRESSION	Eliza Glodkowska- Mrowka (presenting author), Iwona Solarska, Piotr Mrowka, Katarzyna Bajorek, Joanna Niesiobedzka-Krezel, Ilona Seferynska, Katarzyna Borg, and Tomasz Stoklosa
12.	55th American Society of Hematology Annual Meeting and Exposition	December 6-10, 2013, New Orleans, LO, USA	INHIBITORS OF SRC FAMILY AND AKT REGULATE THE ACTIVITY OF CD20 PROMOTER.	Pyrzynska B (presenting author), Bojarczuk K, Winiarska M, Bil J, Miazek N, Zapala P, Bobrowicz M, Dwojak M, Siernicka M, Golab J
13.	56th American Society of Hematology Annual Meeting and Exposition	December 5-9, 2014, San Francisco, CA, USA	HDAC INHIBITORS AS POTENTIAL NEW AGENTS IMPROVING THE EFFICACY OF	Malgorzata Bobrowicz (presenting author), Michal Dwojak, Agata Malenda, Kamil Bojarczuk, Marta



			MONOCLONAL ANTIBODIES	Siernicka, Beata Pyrzynska, Ewa Lech-Maranda, Tomasz Stoklosa, Magdalena Winiarska, Jakub Golab
14.	56th American Society of Hematology Annual Meeting and Exposition	December 5-9, 2014, San Francisco, CA, USA	SK053, AN INHIBITOR OF ENZYMES INVOLVED IN ALLOSTERIC DISULFIDE BONDS FORMATION, TARGETS EXPRESSION OF HISTONE GENES AND INDUCES DIFFERENTIATION OF HUMAN AML CELL	Justyna Chlebowska (presenting author), Pawel Gaj, Piotr Stawinski, Michal Lazniewski, Malgorzata Firczuk, Karolina Furs, Radoslaw Sadowski, Szymon Klossowski, Ryszard Ostaszewski, Jakub Golab, Krzysztof Giannopoulos, Rafal Ploski and Dominika Nowis
15.	56th American Society of Hematology Annual Meeting and Exposition	December 5-9, 2014, San Francisco, CA, USA	PEROXIREDOXINS-1 AND 2 AFFECT PROLIFERATION AND SURVIVAL OF LYMPHOMA CELLS	Małgorzata Firczuk (presenting author), Anna Trzeciecka, Małgorzata Bajor, Angelika Muchowicz, Radosław Zagożdżon, Joanna Barankiewicz, Antoni Domagała, Szymon Klossowski, Agata Malinowska, Justyna Chlebowska, Ryszard Ostaszewski, Jakub Golab, Dominika Nowis
16.	56th American Society of Hematology Annual Meeting and Exposition	December 5-9, 2014, San Francisco, CA, USA	INFLUENCE OF BTK INHIBITORS ON ANTITUMOR ACTIVITY OF NATURAL KILLER CELLS	Marta Siernicka (presenting author), Kamil Bojarczuk, Malgorzata Bobrowicz, Michal Dwojak, Beata Pyrzynska, Mohammed Taha, Cyril Fauriat, Jakub Golab, Magdalena Winiarska
17.	19th Congress of the European Hematology	June 12-15, 2014 Milan, Italy	HDAC6 INHIBITION AUGMENTS THE	Małgorzata Bobrowicz, Michał Dwojak, Kamil





	Association		EFFICACY OF ANTI-CD20 MONOCLONAL ANTIBODIES BY UP-REGULATING CD20 LEVEL IN MALIGNANT B-CELLS	Bojarczuk, Marta Siernicka, Magdalena Winiarska, Jakub Golab
18.	19th Congress of the European Hematology Association	June 12-15, 2014 Milan, Italy	SK053 – AN ALLOSTERIC PROTEIN DISULPHIDE ISOMERASE INHIBITOR INDUCES DIFFERENTIATION OF HUMAN ACUTE MYELOID LEUKEMIA CELLS	Jakub Golab, Justyna Chlebowska, Malgorzata Firczuk, Karolina Furs, Angelika Muchowicz, Radoslaw Sadowski, Szymon Klossowski, Ryszard Ostaszewski, Krzysztof Giannopoulos, Dominika Nowis
19.	19th Congress of the European Hematology Association	June 12-15, 2014 Milan, Italy	SRC INHIBITORS DOWNREGULATE CD20 AND MODULATE THE ACTIVITY OF THE CD20 PROMOTER	Winiarska M, Bojarczuk K, Pyrzynska B, Bil J, Sirnicka M, Miazek N, Zapala P, Pilch Z, Bobrowicz M, Dwojak M, Golab J
20.	16th International Congress of Endocrinology & The Endocrine Society's 96th Annual Meeting & Expo (ICE/ENDO)	June 22–25, 2014, Chicago, USA	NEXT-GENERATION SEQUENCING REVEALS A NOVEL, THYROGLOBULIN-EMBEDDED MICRORNA GENE Deregulated in PAPILLARY THYROID CARCINOMA	Monika Kolanowska, Anna Wojcicka, Anna Kubiak, Michal Swierniak, Monika Maciag, Wieslaw Wiechno and Krystian Jazdzewski (presenting author)
21.	16th International Congress of Endocrinology & The Endocrine Society's 96th Annual Meeting & Expo (ICE/ENDO)	June 22–25, 2014, Chicago, USA	VARIANTS IN THE ATM-CHEK2-BRCA1 AXIS DETERMINE GENETIC PREDISPOSITION AND CLINICAL PRESENTATION OF PAPILLARY	Anna Wójcicka (presenting author), Małgorzata Czetwertyńska, Michał Świerniak, Joanna Długosińska, Monika Maciag, Agnieszka Czajka, Kinga Dymecka, Rafał



			THYROID CARCINOMA THIS POSTER PRESENTATION WAS AWARDED WITH PRESIDENTIAL POSTER COMPETITION AWARD OF ENDOCRINE SOCIETY.	Płoski, Albert de la Chapelle and Krystian Jażdżewski
22.	EMBO Conference: Cellular signalling and cancer therapy	May 23-27, 2014, Cavtat, Croatia	EVALUATION OF ADENANTHIN AS AN INTRACELLULAR SIGNALING MODULATOR AND POTENTIAL THERAPEUTIC AGENT IN ESTROGEN RECEPTOR POSITIVE BREAST CANCER	Malgorzata Bajor (presenting author), Patrick C. O'Leary, Agata Zych, Jakub Golab, William M. Gallagher, Radoslaw Zagodzón
23.	EMBO Conference: Cellular signalling and cancer therapy	May 23-27, 2014, Cavtat, Croatia	PEROXIREDOXIN-1 REGULATES ESTROGEN RECEPTOR ALPHA PROTEIN CONTENT IN BREAST CANCER CELLS UNDERGOING OXIDATIVE STRESS AND IS A PROGNOSTIC BIOMARKER IN THIS DISEASE	Radoslaw Zagodzón (presenting author), Patrick C. O'Leary, Gaj Pawel, Bryan T Hennessy, Gordon B. Mills, Ana M. Gonzalez-Angulo, Han-Dong Sun, Fredrik Pontén, Karin Jirström, William M. Gallagher,
24.	Keystone Symposia Conference "Inflammation, Infection and Cancer (X1)"	March 9-14, 2014, Whistler, Canada	CD200-CD200R PATHWAY INFLUENCES TUMOR GROWTH BY INFILTRATING MYELOID CELLS	Zofia Pilch, Katarzyna Roszczenko, Linde Meyaard, Jakub Gołab, Tomasz P. Rygiel (presenting author)
25.	FEBS-EMBO 2014 Conference	30 August – 4 September 2014, Paris,	UNRAVELING THE MECHANISM OF CHRONIC	Marcin M. Machnicki (presenting author), Joanna Niesiobedzka-



		France	MYELOID LEUKEMIA PROGRESSION BY NEXT-GENERATION SEQUENCING OF LEUKEMIC PROGENITOR AND STEM CELLS	Krezel, Iwona Solarska, Piotr Stawinski, Rafal Ploski, Tomasz Stoklosa.
26.	10th Siena Meeting entitled "From genome to proteome" 20 Years of Proteomics	31st August–September 4th, 2014, Siena, Italy	AN ANTIBODY-BASED PROTEOMIC APPROACH FOR IDENTIFICATION OF PRDX1 AS A BIOMARKER IN ESTROGEN RECEPTOR POSITIVE BREAST CANCER	Malgorzata Bajor (presenting author), Patrick C. O’Leary, Pawel Gaj, Bryan T. Hennessy, Jakub Golab, William M. Gallagher, Radoslaw Zagozdzon
27.	The Joint 3rd World Congress on Twin Pregnancy and 15th Congress of the International Society of Twin Studies (ISTS)	15-19 November, 2014, Budapest, Hungary	THE INFLUENCE OF GENOMIC VARIABILITY ON PHENOTYPIC DISCORDANCE – TOWARDS POLISH REGISTRY OF MONOZYGOTIC TWINS (MZT) DISCORDANT FOR CHRONIC MEDICALLY RELEVANT CONDITIONS	Rafał Płoski, M. Rydzanicz, J. Kosinska, P. Gasperowicz, P. Stawinski, K. Szymański
28.	San Antonio Breast Cancer Symposium 2014	9-13 December, 2014, San Antonio, Texas, USA	ADENANTHIN, A NEW PEROXIREDOXIN INHIBITOR, INDUCES A SWITCH BETWEEN ESTROGEN RECEPTOR ALPHA-MEDIATED AND SRC/AKT-DRIVEN SIGNALING IN BREAST CANCER CELLS	Małgorzata Bajor
29.	Keystone Antibodies	February 9-13, 2015, Banff,	HDAC INHIBITORS AS POTENTIAL	Malgorzata Bobrowicz, MSc;



	Meeting	Canada,	NEW AGENTS IMPROVING THE EFFICACY OF MONOCLONAL ANTIBODIES	Michal Dwojak, MD; Agata Malenda, MD; PhD, Ewa Lech-Maranda, MD, PhD; Magdalena Winiarska, PhD
30.	NGS Milan 2015	March 9-10, 2015, Milan, Italy	EXOME AND CUSTOM-GENE SEQUENCING AS TOOLS FOR ANALYSIS OF CHRONIC MYELOID LEUKEMIA PROGRESSION	Marcin M. Machnicki (presenting author), Joanna Niesiobedzka-Krezel, Iwona Solarska, Piotr Stawinski, Rafal Ploski, Tomasz Stoklosa
31.	American Association of Cancer Research (AACR) Annual Meeting 2015	April 18-22, 2015, Philadelphia, PA, USA	PTEN REGULATES THE CD20 ANTIGEN EXPRESSION AND AFFECTS RITUXIMAB-BASED THERAPY OF LYMPHOMA MALIGNANCIES	Beata Pyrzynska (presenting author), Kamil Bojarczuk, Marta Siernicka, Michal Dwojak, Malgorzata Bobrowicz, Nina Miazek, Piotr Zapala, Agnieszka Zagodzdon, Jakub Golab, Magdalena Winiarska
32.	American Association of Cancer Research (AACR) Annual Meeting 2015	April 18-22, 2015, Philadelphia, PA, USA	SK053, A SMALL MOLECULE INHIBITOR OF ENZYMES INVOLVED IN ALLOSTERIC DISULFIDE BONDS FORMATION, SHOWS POTENT ANTI-LEUKEMIC EFFECTS AND INDUCES DIFFERENTIATION OF HUMAN AML CELLS	Dominika Nowis (presenting author), Justyna Chlebowska, Pawel Gaj, Michal Lazniewski, Malgorzata Firczuk, Karolina Furs, Radoslaw Sadowski, Pawel Leszczynski, Piotr Stawinski, Szymon Klossowski, Ryszard Ostaszewski, Krzysztof Giannopoulos, Rafal Ploski, Dariusz Plewczynski, Jakub Golab
33.	Annual Meeting of the International Society of Extracellular Vesicles	22-26 April 2015, Washington DC, United States		Małgorzata Czystowska-Kuźmicz



34.	49th European Human Genetics Conference	June 6-9, 2015, Glasgow, UK –	ASSOCIATION BETWEEN GWAS-DERIVED RS966423 GENETIC VARIANT AND OVERALL MORTALITY IN PATIENTS WITH DIFFERENTIATED THYROID CANCER	M. Swierniak, A. Wojcicka, M. Czetwertynska, J. Dlugosinska, E. Stachlewska, W. Gierlikowski, B. Gornicka, L. Koperski, M. Bogdanska, W. Wiechno, K. Jazdzewski (presenting author)
35.	49th European Human Genetics Conference	June 6-9, 2015, Glasgow, UK –	A POLYMORPHISM IN MIR-146A TAILORS GENETIC PREDISPOSITION TO DIFFERENTIATED THYROID CANCER, MODULATES ITS CLINICAL OUTCOME AND ALTERS PROLIFERATION OF TUMOR CELLS	A. Wojcicka (presenting author), A. Kubiak, M. Kotlarek, A. Czajka, M. Czetwertynska, J. Dlugosinska, M. Swierniak, N. Fedoryszak-Kuska, B. Gornicka, K. Jazdzewski
36.	20th Congress of the European Hematology Association	Vienna, Austria, June 11-14, 2015	SELECTION OF RUNX1-MUTATED CLONE ASSOCIATED WITH RELAPSE AND BLAST CRISIS IN CHRONIC MYELOID LEUKEMIA PATIENT AFTER ALLO-HSCT AS REVEALED BY TARGETED ENRICHMENT AND DEEP SEQUENCING	Iwona Solarska (presenting author), Marcin M. Machnicki, Barbara Nasiłowska-Adamska, Barbara Pieńkowska-Grela, Ilona Seferyńska, Piotr Stawiński, Rafał Płoski and Tomasz Stokłosa
37.	20th Congress of the European Hematology Association	Vienna, Austria, June 11-14, 2015	SK053, AN INHIBITOR OF ENZYMES INVOLVED IN ALLOSTERIC DISULFIDE BONDS FORMATION, TARGETS	Justyna Chlebowska (presenting author), Pawel Gaj, Michal Lazniewski, Malgorzata Firczuk, Karolina Furs, Radoslaw Sadowski, Pawel Leszczynski,



			EXPRESSION OF HISTONE GENES, SHOWS POTENT ANTI-LEUKEMIC EFFECTS AND INDUCES DIFFERENTIATION OF HUMAN AML CELLS	Piotr Stawinski , Szymon Klossowski , Ryszard Ostaszewski , Krzysztof Giannopoulos , Rafal Ploski , Dariusz Plewczynski , Jakub Golab , Dominika Nowis
38.	20th Congress of the European Hematology Association	Vienna, Austria, June 11-14, 2015	OFATUMUMAB OVERCOMES CD59-DEPENDENT RESISTANCE TO COMPLEMENT-DEPENDENT CYTOTOXICITY IN HUMAN B-CELL LYMPHOMA MODEL	Dwojak M (presenting author), Bobrowicz M, Siernicka M, Pyrzynska B, Bojarczuk K, Golab J, Winiarska M
39.	15th International Conference on Oxidative Stress Reduction, Redox Homeostasis and Antioxidants	Pasteur Institute, Paris, France on June 22-24, 2015	ADENANTHIN, A NEW INHIBITOR OF THIOL-DEPENDENT ANTIOXIDANT ENZYMES, DEEPLY IMPAIRS THE EFFECTOR FUNCTIONS OF HUMAN NATURAL KILLER CELLS	Radoslaw Zagozdzon (presenting author), Marta Siernicka, Malgorzata Bajor, Malgorzata Firczuk, Angelika Muchowicz, Malgorzata Bobrowicz, Cyril Fauriat, Jakub Golab, Daniel Olive, Magdalena Winiarska
40.	15th International Conference on Oxidative Stress Reduction, Redox Homeostasis and Antioxidants	Pasteur Institute, Paris, France on June 22-24, 2015	ROLE OF THIOL-DEPENDENT PEROXIREDOXINS IN REGULATION OF AKT SIGNALING IN BREAST CANCER	Malgorzata Bajor (presenting author), Patrick C. O'Leary, Agata O. Zych, William M. Gallagher, Jakub Golab, Radoslaw Zagozdzon
41.	15th International Conference on Oxidative Stress Reduction, Redox Homeostasis and Antioxidants	Pasteur Institute, Paris, France on June 22-24, 2015	THIOL-REACTIVE PEPTIDOMIMETIC SK053 TARGETS DIMERIC PEROXIREDOXINS IN HUMAN LYMPHOMA CELL LINES	Małgorzata Firczuk



Participation in international conferences was a great opportunity to present our own research findings to a broad audience and to share scientific ideas with several experts in the field of experimental and clinical oncology and molecular biology and genetics. It was also a unique possibility to promote Medical University of Warsaw and BASTION project. On the other hand participation in 7 workshops and training courses was extremely valuable for bringing know-how and future career development.

### 3. Planned use and dissemination

BASTION project continues until February 2016. Therefore, dissemination of information on the project outcomes will be continued, albeit to a much lesser extent due to lack of pertinent funding for this purpose. The BASTION web page (<http://bastion.wum.edu.pl/> and <http://bastion.wum.edu.pl/en/>) will still be open for at least next 5 years and will be updated with the most important informations about our publications and research achievements.

Also research articles resulting from on going research projects, started during BASTION will contain information about the source funding.

BASTION project increased the research potential of MUW in a number of ways:

- Gaining of know-how and increasing scientific dialogue between MUW and the top academic research centers being partnering Institutions
- Recruitment of 12 researchers with international experience in basic and clinical oncology as well as 2 IT specialists
- Purchase of research equipment
- Increased awareness of the significance of efficient IP protection and innovation management schemes

To fully use this increased research potential we have applied for research grants to public institutions in Poland and European Commission. The following grant applications were successfully funded:

#### **Grants awarded to BASTION members:**

##### **Grants from the National Science Centre (NCN)**

<b>Title</b>	<b>Funding Institution</b>	<b>Principal Investigator</b>	<b>Period</b>	<b>Funds (PLN)</b>
Functional analysis of newly discovered microRNA gene deregulated in papillary thyroid carcinoma	NCN	Monika Kolanowska (Ph.D. student) <b>Krzysztof Jazdzewski</b> (supervisor)	2013-2016	149 500,-



Functional analysis of RARB in hepatocellular carcinoma and the role of microRNA in regulation of its expression	NCN	Agnieszka Czajka (Ph.D. student) <b>Krystian Jazdzewski</b> (supervisor)	2013-2016	149 942,-
Impact of polymorphic microRNA-146a on <i>NTRK2</i> function in papillary thyroid carcinoma	NCN	Anna Kubiak (Ph.D. student) <b>Krystian Jazdzewski</b> (supervisor)	2013-2016	149 955,-
The use of microRNA inhibitors for restoration of the physiological expression of sodium iodide symporter NIS in thyroid cancer cells - an attempt to develop a new adjuvant therapy for cancer	NCN	Marta Kotlarek (Ph.D. student) <b>Krystian Jazdzewski</b> (supervisor)	2015-2017	149 994,-
The role of microRNAs in regulation of genes coding for iodine transporters (NIS, AIT and Pendrin) in papillary thyroid carcinoma	NCN	<b>Anna Wojcicka</b>	2013-2016	499 200,-
Investigation of the molecular mechanisms of anti-leukemic activity of SK053 – a small molecule compound targeting enzymes involved in allosteric disulphide bonds formation	NCN	<b>Dominika Nowis</b>	2014-2017	1 180 714,-
Amplification of Mixed-Lineage Kinase 4 in breast cancer	NCN	Anna Marusiak (post-doc), <b>Dominika Nowis</b> (supervisor)	2015-2018	620 000,-
Identification of new, clinically relevant genetic and epigenetic aberrations by next-generation sequencing in chronic myeloid leukemia patients with poor disease outcome	NCN	<b>Tomasz Stoklosa</b>	2015-2018	1 802 118,-
The role for thiol-dependent antioxidant enzymes in estrogen receptor-positive breast cancer	NCN	<b>Radosław Zagodzón</b>	2015-2018	1 213 233,-
Evaluation of peroxiredoxins 1 and 2 along with the thioredoxin-thioredoxin reductase system as new therapeutic targets in B cell lymphomas	NCN	<b>Radosław Zagodzón</b>	2013-2016	987 000,-
Influence of AKT signaling pathway on CD20 expression and antitumor activity of therapeutic	NCN	<b>Beata Pyrzynska</b>	2014-2017	1 074 759,-





monoclonal antibodies				
Studies on the influence of selected inhibitors of kinases involved in signaling pathways in tumor cells on NK cell cytotoxicity	NCN	Marta Siernicka (Ph.D. student) <b>Magdalena Winiarska</b> (supervisor)	2015-2017	150 000,-
Investigation of the proteins influencing CD20 antigen degradation'	NCN	Malgorzata Bobrowicz (Ph.D. student) <b>Magdalena Winiarska</b> (supervisor)	2014-2016	100 000,-
Influence of the B-cell receptor (BCR) signaling pathways on CD20 levels in tumor cells and antitumor activity of anti-CD20 monoclonal antibodies	NCN	<b>Magdalena Winiarska</b>	2013-2016	786 000
The role of indoleamine-2,3-dioxygenase in development of antitumor immune response triggered by photodynamic therapy	NCN	Angelika Muchowicz <b>Jakub Golab</b> (supervisor)	2015-2017	691 987
Elucidation of the role of tumor-derived and exosomal arginases in avoiding immune responses by ovarian cancer	NCN	<b>Malgorzata Czystowska</b>	2014-2016	1 359 699,-
Characterization of mutational profile in hypopharyngeal cancers by exome enrichment and massive parallel sequencing.	NCN	Marcin Machnicki <b>Tomasz Stoklosa</b> (supervisor)	2014-2016	150 000,-
Whole-exome sequencing for identification of genetic factors associated with early mortality of adults in Polish population.	NCN	<b>Rafal Ploski</b>	2014-2017	1 198 800,-
Mutacje de novo w poszukiwaniu nowych loci powiazanych z chorobami kardiologicznymi	NCN (Preludium)	Mgr Maria Franaszczyk, <b>Rafal Ploski</b> (supervisor)	2013-2016	149 500
Wplyw czynnikow genetycznych na rozwój i przebieg choroby Gravesa-Basedowa: warianty genu 11beta-dehydrogenazy hydroksysteroidowej typu I (HSD11B1) a predyspozycja do oftalmopatii tarczycowej	NCN (Preludium)	Konrad Szymański, <b>Rafal Ploski</b> (supervisor)	2013-2016	140 556
Exome-wide search for somatic mutations in pathogenesis of endometriosis	NCN	<b>Pawel Wlodarski</b>	2014-2016	992 405,-



„Epigenetic regulation of expression of genes involved in extracellular matrix remodeling and angiogenesis during development of endometriosis”	NCN (Preludium)	Radosław Maksym, MD (Ph.D. student) <b>Paweł Włodarski</b> (supervisor)	2012- 2015	247 500,-
„The regulatory role of single nucleotide polymorphism in 3'UTR regions of TGFB-1 receptor genes in hepatocytes”	NCN (Preludium)	Emir Sajjad, MD (Ph.D. student) <b>Paweł Włodarski</b> (supervisor)	2012- 2015	192 060,-
The role of microRNA mutations in pathology of the thyroid gland and in genetic predisposition to papillary thyroid carcinoma	NCN	<b>Krzysztof Jazdzewski</b>	2014- 2017	1 491 373,-
CD200R signaling in inflammation and immune cancer responses: a tricky balance	NCN	Tomasz Rygiel <b>Jakub Golab</b> (supervisor)	2012- 2014	998 100,-
Circulating tumor cells	NCN	<b>Piotr Religa</b>	2012- 2014	422 400,-
Red cell heterogeneity as a risk factor for thrombotic complications	NCN	<b>Zbigniew Gaciong</b> (supervisor), <b>Marzena Łazarczyk</b> (post-doc), Helena Kosowska (PhD student)	2015- 2018	952 200,-
The role of CCL7 in development of colon cancer	NCN	Ewa Kurzejamska, <b>Piotr Religa</b> (supervisor)	2014- 2017	99 970,-
RDW as risk factor for thrombotic episodes	NCN	<b>Zbigniew Gaciong</b> , <b>Piotr Religa</b>	2015- 2018	950 000,-
<b>TOTAL</b>				<b>19 048 965,-</b>

#### Grants from the Ministry of Science and Higher Education (MNiSW)

<b>Title</b>	<b>Funding Institution</b>	<b>Principal Investigator</b>	<b>Period</b>	<b>Funds (PLN)</b>
The role of microRNAs in regulation of <i>SLC5A8</i> , a tumor suppressor gene, in thyroid cancer	MNiSW	Wojciech Gierlikowski (M.D. student) <b>Krzysztof Jazdzewski</b> (supervisor)	2012- 2014	153 200,-
Influence of inhibition of histone deacetylases (HDACs) on the	MNiSW	Malgorzata Bobrowicz (Ph.D.)	2012- 2015	200 000,-



efficacy of selected antitumor therapies in the model of human tumors originating from B-cells		student) <b>Magdalena Winiarska</b> (supervisor)		
The role of thioredoxin/thioredoxin reductase and peroxiredoxins in multiple myeloma	MNiSW	<b>Dominika Nowis</b>	2013-2015	322 400,-
The role of autophagy in tumor cells' response to the photodynamic therapy	MNiSW	Antoni Domagala (M.D. student) <b>Malgorzata Firczuk</b> (supervisor)	2014-2016	200 000,-
Search for target proteins for the new compounds with antitumor activity	MNiSW	<b>Malgorzata Firczuk</b>	2012-2015	384 000,-
The influence of the EGF-SubA fusion protein on the photodynamic efficacy in a murine model	MNiSW	<b>Malgorzata Firczuk</b>	2012-2014	200 000,-
<b>TOTAL</b>				<b>1 459 600,-</b>

#### Grants from the National Centre for Research and Development (NCBiR)

<b>Title</b>	<b>Funding Institution</b>	<b>Principal Investigator</b>	<b>Period</b>	<b>Funds (PLN)</b>
The use of next-generation sequencing for elucidation of a sensitive and specific molecular panel for diagnostics of thyroid cancers	NCBiR	<b>Anna Wojcicka</b>	2014-2017	1 200 000,-
Development of new cancer therapies based on selective antitumor immunomodulators	NCBiR	<b>Jakub Golab</b>	2015-2018	31 929 500,-
Development of selective inhibitors of [undisclosed] for asthma treatment	NCBiR	<b>Jakub Golab</b>	2014-2015	5 500 000,-
Forensic DNA test to determine human age	NCBiR	dr inż. Renata Zbieć-Piekarska, <b>Rafał Płoski</b> (PI of WUM work package)	2013-2016	1 535 300 (WUM work-package only)
<b>TOTAL</b>				<b>40 164 800,-</b>



### Other grants:

Title	Funding Institution	Principal Investigator	Period	Funds (PLN)
Novel therapeutic strategies to target tumor lymphangiogenesis	Polish-Swiss Research Programme	<b>Jakub Golab</b>	2012-2015	3 314 319,-
Two-foton microscopy in medicine („Gdzie jeden nie może, tam drugiego pošlij – wykorzystanie zjawiska absorpcji dwufotonowej w biologii i medycynie”)	Foundation of Polish Science (INTER SKILLS project)	Eliza Głodkowska-Mrówka (Ph.D. student) <b>Tomasz Stokłosa</b> (supervisor)	2013-2014	100 000,-
			<b>TOTAL</b>	<b>6 414 319,-</b>

### Unsuccessful or submitted and not yet funded grant applications:

Title	Where applied	Principal Investigator
Elaboration of a molecular diagnostic panel for thyroid cancer	National Centre for Research and Development	<b>Krystian Jażdżewski</b>
Functional analysis of novel microRNAs and their role in development of papillary thyroid carcinoma	AICR (currently Worldwide Cancer Research)	<b>Krystian Jażdżewski</b>
MicroRNA genes in predisposition to thyroid carcinoma - population-based study	National Institutes of Health	<b>Krystian Jażdżewski</b>
Assessment of TIMP4 epigenetic regulation in prostate cancer using massively parallel sequencing	NCN (Preludium)	Marek Andrzej Janiak, MS <b>Paweł Włodarski</b> (supervisor)
Identification of novel mutations in the genes of the JAK family protein kinases using massively parallel sequencing and its potential role in pathogenesis of myeloproliferative disorders in children.	NCN (Preludium)	Łukasz Hutnik, MD <b>Paweł Włodarski</b> (supervisor)
Interrogating the mechanisms of function of peroxiredoxin 1 (PRDX1) in estrogen receptor-positive breast cancer	NCN	<b>Malgorzata Bajor</b>
Analysis and evaluation of significance of molecular differences between Burkitt's lymphoma and diffuse large B-cell lymphoma	NCN	<b>Paweł Gaj</b>
Novel computational approaches for analysis of the Next Generation Sequencing data: development of the indel calling algorithm	NCN	<b>Piotr Stawinski</b>



Interrogating the mechanisms of function of peroxiredoxin 1 (PRDX1) in estrogen-positive breast cancer	NCN	<b>Malgorzata Bajor</b>
The role of CMV infection in tumor growth and metastasis	NCN (Opus)	<b>Piotr Religa</b> (supervisor), Zbigniew Gaciong
Development of novel preventive strategies to reduce hypertension-related cardiovascular burden in Poland	NCBiR (STRATEGMED)	Zbigniew Gaciong (investigator)
Search for genetic variants, novel genes and biological pathways associated with left ventricular hypertrophy in patients with symptomatic aortic stenosis in 7q31.1 locus selected by Genome Wide Association Study (GWAS)	NCN (ETIUDA 3 )	<b>Helena Kossowska</b>
Nowatorskie rozwiązania informatyczne do analizy wyników sekwencjonowania następnej generacji: rozwój algorytmów identyfikacji insercji oraz delekcji	NCN (Preludium)	<b>Piotr Stawiński</b>
Identyfikacja zróżnicowania eksomowego pomiędzy dawcą a biorcą przeszczepu alogenicznego komórek krwiotwórczych do następnego wykorzystania w immunoterapii wznowy białaczki	NCBiR (PBS)	<b>Rafał Płoski</b>
Role of epigenetic mechanisms in chronic myeloid leukemia progression and resistance to targeted therapy	NCN (Opus)	<b>Joanna Drzewińska-Chańko</b>
Rola metylacji DNA w progresji przewlekłej białaczki szpikowej i mechanizmach lekooporności na terapię celowaną	MNiSW (Iuventus Plus)	<b>Joanna Drzewińska-Chańko</b>
Deciphering the role of telomerase complex in genomic instability and drug resistance in chronic myeloid leukemia	NCN (Opus)	<b>Tomasz Stokłosa</b>
Identification of hallmarks of carcinogenesis leading to discovery and development of new molecular methods for early diagnosis and personalized treatment of endocrine cancers	Teaming of Excellence competition under the framework programme Horizon 2020	<b>Krystian Jażdżewski</b>
NOnCo	H2020-PHC-2015	Stefano Volinia <b>(Krystian Jażdżewski as a participant)</b>
Strategies towards Excellence in Immunology - „STREAM”	H2020-TWINN- 2015	<b>Jakub Golab</b>
Studies of the role of peroxiredoxin 1 and other antioxidant enzymes in B cell acute lymphoblastic leukemia	NCN (Opus)	<b>Malgorzata Firczuk</b>
Impact of anti-tumor immunity on the	Polish-Norwegian	<b>Jakub Golab</b>



therapeutic outcome of photosensitizer-based therapeutics in cancer treatment	Research Programme	
International Center of Excellence - Institute for Molecular Oncology (IMO)	Teaming of Excellence competition under the framework programme Horizon 2020	<b>Jakub Golab</b> (participant of the consortium)

It must be emphasized that during the BASTION project we have applied to European Commission with research proposal. Two such proposals for Teaming of Excellence competition under the framework programme Horizon 2020 were pre-evaluated at the national level and did not gain approval for further evaluation. Another grant application submitted with cooperation with one of our twinning partners (prof. Stefano Volinia) and was unsuccessful in H2020-PHC-2015 call. The fourth grant (Strategies towards Excellence in Immuno-Oncology - „STREAM”) is submitted and under evaluation by European Commission within the H2020-TWINN-2015 call.

All these funded or yet-to-be funded projects will heavily depend on research equipment purchased during the BASTION project. Many projects are based on the use of IT infrastructure developed under BASTION. We will also use the expertise developed in-house and acquired from our twinning partners. Seven out of sixteen researchers will continue to be employed by the Medical University of Warsaw. Also one IT specialist will continue employment at MUW and one will become a volunteer until successful funding is secured.

During the project we have prepared a Policy Paper (deliverable D2.10) for a new state policy concerning personalized cancer prevention in Poland. The purpose of this document is to present a new policy for cancer prevention, targeted, among others, at making diagnostic cancer tests that are essential for implementing personalized prevention programme of each patient, commonly accessible in Poland. Personalized prevention is closely related to the individual, specifically defined risk of particular patients developing particular cancers. The document presents assumptions of oncology-related programmes currently operating in Poland, an analysis has been conducted of gaining potential savings generated by the introduction of genetic diagnostics to oncology and the results have been presented of social study, carried out for the purposes of this document, concerning Polish awareness in terms of cancer prevention and genetic tests. Policy paper proposes a scheme of a social campaign targeted at informing the public about the need of carrying out proper preventive tests. The primary objective of the campaign is to raise public awareness in order to reduce the number of patients reporting to a physician at an advanced stage of cancer. The campaign should mainly focus on raising awareness of the consequences of late cancer diagnoses, i.e. on negative effects for the patient and their significant ones, as well as on presenting all kinds of benefits of preventive screening combined with informing about the possibilities of undergoing a particular test. The campaign introduces 6 target groups for whom separate, tailor-made modes of communication were developed, and major sources of receiving information.



#### 4. Conclusions

This deliverable contains the actions undertaken for using and disseminating the BASTION foreground. Described are the major research achievements of BASTION participants (publications and conference reports) as well as the actions that have been undertaken, including off-line and on-line activities to disseminate BASTION foreground. Numerous research grants acquired by BASTION researchers shows the planned areas and directions for the use of the foreground. Policy Paper outlines future activities, mainly focused on rising awareness of molecular diagnostic procedures in oncology, that is going to be implemented pending acquisition of pertinent funding.

Prof. Jakub Golab  
WP6 Leader and BASTION Project Coordinator  
Msc Iwona Drozdowska-Rusinowicz  
WP6 Co-leader

*Warsaw, August 2015*